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14 ABSTRACT: The transient receptor potential vanilloid 2 (TRPV2) is a nonselective Ca2+ permeable channel member of the
15 TRPV subfamily, still considered an orphan TRP channel due to the scarcity of available selective and potent pharmacological
16 tools and endogenous modulators. Here we describe the discovery of novel synthetic long-chain capsaicin derivatives as potent
17 TRPV2 antagonists in comparison to the totally inactive capsaicin, the role of their hydrophobic chain, and how the structure−
18 activity relationships of such derivatives led, through a ligand-based approach, to the identiﬁcation of endogenous long-chain
19 fatty acid ethanolamides or primary amides acting as TRPV2 antagonists. Both synthetic and endogenous antagonists exhibited
20 diﬀerential inhibition against known TRPV2 agonists characterized by distinct kinetic proﬁles. These ﬁndings represent the ﬁrst
21 example of both synthetic and naturally occurring TRPV2 modulators with eﬃcacy in the submicromolar/low-micromolar
22 range, which will be useful for clarifying the physiopathological roles of this receptor, its regulation, and its targeting in
23 pathological conditions.
1. INTRODUCTION
24 TRPV2 belongs to the polymodal transient receptor potential
25 (TRP) superfamily of calcium-permeable nonselective cation
26 channels, activated by a wide variety of physical and chemical
27 stimuli. Due to its mechanosensor property, TRPV2 is
28 considered a stretch-modulated channel and a regulator of
29 calcium homeostasis in diﬀerent tissues and organs, in
30 particular the heart, where it is 10-fold more abundant than
31 in skeletal muscle.
1 Diﬀerent lines of evidence suggest for
32 TRPV2 a key role in physiological cardiac function as well as in
33 cardiomyopathies and dystrophic diseases.
2−4 Besides the
34 heart, TRPV2 is also found in the brain, vascular smooth
35 muscle cells, the gastrointestinal tract, macrophages, and the
36 urothelial tract,5 and it is involved in a number of
37physiopathological processes,6 including cancer,7−9 particularly
38of the urinary tract.10−13
39Despite its biological and pharmacological relevance,
40TRPV2 is still considered an orphan TRP channel due to
41the scarcity of selective drugs and known endogenous ligands.
42The 2-aminoethoxydiphenyl borate (2APB) is one of the ﬁrst
43nonselective activators identiﬁed for rat TRPV2 (EC50 = 129
44μM),14 although inactive at the human orthologue, suggesting
45a strong species speciﬁcity.15,16 Cannabis sativa derivatives such
46as Δ9-tetrahydrocannabinol (Δ9-THC), cannabidiol (CBD),
47and Δ9-tetrahydrocannabivarin (Δ9-THCV) are TRPV2
48activators17,18 and so is p-(di-n-propylsulfamyl)benzoic acid
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49 (probenecid).19 However, all these agonists are known to
50 modulate other TRP channels. Most TRPV channels are
51 proposed to be modulated also by phosphoinositide lipids.20
52 TRPV2-mediated Ca2+ inﬂux has been reported following
53 stimulation by endogenous lysophospholipids such as
54 lysophosphatidylcoline (LPC) and lysophosphatidylinositol
55 (LPI),21 LPC being a relatively potent activator (EC50 = 3.4
56 μM).22 To date, the nature of endogenous regulators of
57 TRPV2 activity still remains elusive.23
58 Also synthetic inhibitors of TRPV2 are either not speciﬁc or
59 endowed with low potency, as exempliﬁed by ruthenium red
60 (IC50 = 0.6 μM),
24 a pore blocker that inhibits other 12 ion
61 channels;25 La3+ and Gd3+;26 citral;27 the alkylated imidazole
62 SKF96365;16 tetraethylammonium and 4-aminopyridine, two
63 potassium channel blockers; 1-(2-(triﬂuoromethyl)phenyl)-
64 imidazole, an inhibitor of capacitative Ca2+ entry;16 and
65 tranilast,28 which has been used in several studies,29−34 even
66 though it has never been validated as TRPV2 antagonist.
67 TRPV2 shares high sequence identity (>50%) with TRPV1,
68 but its threshold of activation by temperature is higher (>52
69 °C)24 and, unlike TRPV1, is not sensitive to capsaicin. The
70 recently solved cryo-EM structures of both TRPV1 and
71 TRPV2,35,36 along with mutagenesis and computational
72 studies, showed that the TRPV1 binding site of capsaicin is
73 not conserved in TRPV2. Furthermore, the replacement of
74 critical residues leads to a mutant (TRPV2-Quad) against
75 which capsaicin behaves as an antagonist rather than an agonist
76 as in TRPV1.37 These intriguing results prompted us to
77 investigate a series of capsaicin derivativs in which the
78 vanillylamide polar head of capsaicin bears a longer alkyl
79 chain, featuring diﬀerent length, unsaturation degree, and type
80of polar substituents. The structure−activity relationship
81(SAR) of these synthetic compounds then suggested the
82screening of structurally related endogenous lipids sharing at
83least one functional group with the capsaicin derivativs, with
84the aim of ﬁnding new endogenous modulators.
2. RESULTS
852.1. Synthesis. Commercial fatty acids such as ricinoleic
86acid, oleic acid, and palmitic acid were used as starting material
87 s1to synthesize the 23 compounds tested. Scheme 1 shows the
88synthesis of the α,β-unsaturated ketone 5 by the ruthenium-
89catalyzed oxidation in anhydrous toluene of the homoallylic
90alcohol of the methyl ricinoleate 4.38 Shvo’s catalyst and
91acrolein were used as catalyst and hydrogen scavenger,
92respectively.39 The addition of bis(pinacolato)diboron
93(Bpin)2 to the enone 5 in the presence of tri-n-butylphosphine
94(P(nBu)3)
40 yielded the β-boronketone 6 in 46% yield.
95Enzymatically controlled hydrolysis41 of the methyl ester 6
96with Novozym 435 lipase led to the carboxylic acid 7
97quantitatively. This acid 7 was coupled, without any further
98puriﬁcation, with 4-hydroxy-3-methoxybenzylamine hydro-
99chloride 3 by HATU42 and DIPEA in anhydrous DMF,
100achieving the amide 8. The oxidative hydrolysis of the boron
101substituent of the compound 8 led to the β-hydroxyketone 9 in
102a 76% yield (Scheme 1).
103The irradiation of alcohol 4 with diphenyl sulﬁde43 in
104isooctane in a photochemical reactor for 3 h led to the isomer
10510 in 37% yield after several recrystallizations at −30 °C. This
106compound was used to synthesize two new long-chain N-
107vanillylamides (12, 15). The hydrolysis of the methyl ester of
Scheme 1. Synthesis of Compound 9
Scheme 2. Synthesis of Compounds 12 and 15
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108 10 led to the corresponding carboxylic acid 11. The
109 subsequent coupling of 11 with the 4-hydroxy-3-
110 methoxybenzylamine hydrochloride 3 using the same con-
111 ditions described above yielded compound 12 in a 34% yield.
112 Compound 10 was also oxidized with CrO3 in pyridine
44 to
113 prepare the trans ketone 13 (49% yield), which was
114 enzymatically hydrolyzed to synthesize the corresponding
115 acid 14 in a 78% yield. Subsequently, 14 was coupled with the
116 vanillyl amine 3 to yield the (E)-N-(4-hydroxy-3-methoxyben-
117 zyl)-12-oxooctadec-9-enamide 15 after puriﬁcation by liquid
s2 118 column chromatography (17% yield) (Scheme 2).
s3 119 Scheme 3 shows the synthesis of the sulfur- and seleno-
120 derivatives of 3. Mercaptopropionic acid 16 was coupled with
121 4-hydroxy-3-methoxybenzylamine hydrochloride 3 using
122 HATU and DIPEA in anhydrous DMF, achieving the amide
123 17 (74% yield). The synthesis of the seleno-derivatives started
124 with bromopropionic acid 18, which was treated with KSeCN
125 in water: The neutralization with Na2CO3, yielded the
126 selenocyanatopropionic acid 19 in 80% without puriﬁcation.
127 Finally, compound 19 was coupled with the 4-hydroxy-3-
128 methoxybenzylamine hydrochloride 3 to obtain compound 20
129 after puriﬁcation by liquid column chromatography (60%
130 yield).
131Amide 17 was S-alkylated with the previously synthesized
132alkylating derivatives 30a−c, 32, and 35 (see Supporting
133Information) in DMF and triethylamine, obtaining the long-
134chain N-vanillylamides 39−43 and 45 in 41−68% yield. N-
135Vanillylamide 44 was successfully achieved after removing the
136TBDMS protecting group with acetic acid at room temper-
137ature (81% yield). New long-chain N-vanillylamides were
138obtained from compound 20, which was ﬁrst treated with
139NaBH4 in ethanol at room temperature to remove the cyano
140protection and regenerate the selenol group.45 Subsequent Se-
141alkylation was carried out in one-pot with the addition of
142diverse set of alkylating reagents (30a−c, 35 ,and 38). N-
143Vanillylamides 46−49 and 51 were synthesized in 71−87%
144yields. Compound 50 was successfully prepared after removing
145the TBDMS protecting group with acetic acid at room
146 s4temperature (79% yield) (Scheme 4).
147 s5Scheme 5 shows the synthesis of amino-branched analogues.
148The ﬁrst step consisted of the treatment of L-cystine 21 or L-
149selenocystine 25 with Boc2O in the presence of triethylamine
150to aﬀord the protected derivatives 221 and 262 (quantitative
151and 65% yield, respectively).46,47 These compounds were
152coupled with 4-hydroxy-3-methoxybenzylamine hydrochloride
1533 using EDCI, HOBt, and triethylamine (TEA) in anhydrous
154DMF, achieving the amides 23 and 27 (74% and 88% yield).
155The reduction of compound 23 with P(nBu)3 in wet
156dichloromethane aﬀorded compound 24 in a 73% yield after
157puriﬁcation by liquid column chromatography. New long-chain
158N-vanillylamides were aﬀorded from compound 24, which was
159S-alkylated with the previously synthesized alkylating deriva-
160tives 30a−c and 32 in the presence of triethylamine, obtaining
161the long-chain N-vanillylamides 52, 53, and 54 in moderate
162yields (50−79% yield). The N-Boc deprotection was carried
163out using triﬂuoroacetic acid48 in dichloromethane yielding N-
164vanillylamides 55, 56, and 57 as triﬂuoroacetic salts in
165quantitative yields. Compound 27 was reduced with NaBH4
Scheme 3. Synthesis of Sulfur and Seleno Intermediates
Scheme 4. Synthesis of No-Branched Sulfur- and Seleno-Derivatives
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166 in ethanol at room temperature to cleave the diselenium
167 bond.
49 The Se-alkylation was carried out with the addition of
168 the alkylating derivatives 30a,b to aﬀord the N-vanillylamides
169 58 and 59 in 74−88% yields. Finally, The N-Boc deprotection
170 was carried out using the same conditions described above to
171 aﬀord the N-vanillylamides 60 and 61 as triﬂuoroacetic salts.
172 Acids 63a,b, which were previously obtained from the
173 hydrolysis of their respective methyl esters 62a,b (see
174 Supporting Information), were coupled with the 4-hydroxy-
175 3-methoxybenzylamine hydrochloride 3 using HATU and
176 DIPEA in anhydrous DMF, achieving the amides 64 and 65
177 after puriﬁcation by liquid column chromatography (64% and
s6 178 63% yield) (Scheme 6).
179Methyl palmitate 28a was treated with an excess of
180hydrazine hydrate in ethanol to synthesize the palmitic acid
181hydrazide 66 (80% yield). The addition of the aromatic
182aldehyde vanillin 1 to compound 66 in the presence of acetic
183acid in reﬂux conditions gave the Schiﬀ’s base compound 67 in
18458% yield.
50A similar compound was synthesized starting from
185oleaic acid 70, which was coupled to tert-butyl hydrazine-
186carboxylate 69 using HATU and DIPEA in DMF to yield the
187oleylhydrazide 71 in a 94% yield. The N-Boc deprotection of
188oleylhydrazide 71 with TFA in DCM for 2 h led to
189oleylhydrazide 72 in 92% yield. Compound 72 reﬂuxed with
190vanillin 1 in the presence of acetic acid in methanol produced
191 s7the Schiﬀ base 73 in 22% yield (Scheme 7).
Scheme 5. Synthesis of Amino-Branched Analogues
Scheme 6. Synthesis of Compounds 64 and 65
Scheme 7. Synthesis of Compounds 67 and 73
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192 2.2. Biological Evaluation. 2.2.1 Capsaicin Derivatives
f1 193 Activate TRPV1 Channel. The capsaicin scaﬀold (Figure
f1 194 1)51 can be ideally divided into three regions: head, neck, and
195 tail, formed by the vanillyl moiety, the amidic group, and the
196 lipophilic alkyl chain, respectively. Structural variations,
197 including incorporation of sulfur atom, into the head and the
198 neck regions have been described in the literature.52−55
199 Instead, the eﬀect of a sulfur atom in the alkyl chain has been
200 less investigated. The recent availability of the 3D structure of
201 TRPV156 along with mutagenesis studies57 allowed the
202 identiﬁcation of the capsaicin binding site, where the alkyl
203 chain is hosted in a phenylalanine-rich hydrophobic region
204 close to Thr550, a residue involved in H-bond interaction with
205 the ligand amide group. The presence of a sulfur atom near the
206 neck region should in principle lead to an increment of activity
207 due to favorable dipole−dipole and aromatic−sulfur inter-
208 actions. Since sulfur can be substituted with selenium via
209 isosteric replacement, we also synthesized the corresponding
210 selenium analogs. Selenium is an essential trace element whose
211 role in medicine and biology is just starting to be elucidated.
212 Some selenium-containing compounds have provided protec-
213 tion against many degenerative conditions, including cancer.
214 Thus, a series of novel capsaicin derivativs, i.e., 9, 12, 15, 39,
215 46, 55, 60, 42, 57, 44, 56, 40, 45, 65, 41, 48, 64, 47, 61, 51,
t1t2 216 50, 67, 73, whose structures are reported in Tables 1 and 2,
217 featuring the same “head” and “neck” as capsaicin but diﬀering
218 in length and nature of the hydrocarbon tail, were tested on
219 human TRPV1 heterologously expressed in human embryonic
220 kidney (HEK)-293 cells by ﬂuorometric assay (see Tables S1
221 and S2 in Supporting Information). The predicted activities as
222 TRPV1 agonists were conﬁrmed for many compounds within
223 the series, exhibiting EC50 values from high-nanomolar to
224 subnanomolar range. A SAR analysis of the results also
225 disclosed the critical role of the region ﬂanking the amide
226 group in modulating the activity. In fact, the insertion of a
227 positive charge next to the amide group was detrimental for
228 activity (compounds 55−57 and 60), and the introduction of
229 an imido group between the aromatic moiety and the amido
230 group led to totally inactive compounds (compounds 67 and
231 73). Conversely, the introduction of a single polar substituent
232 (hydroxyl, ester, or ketone) was well-tolerated, and the
233 introduction of a sulfur or selenium atom in the hydrophobic
234 tail even improved the activity. However, on the basis of the
235 antagonist activity exhibited by capsaicin on TRPV2-Quad,37
236 the new compounds were also tested on TRPV2 to determine
237 if the elongation and the functionalization of the alkyl chain
238 could elicit a functional response at this receptor.
239 2.2.2. Capsaicin Derivatives Inhibit TRPV2 Channels
240 Activated by LPC. The activity of the synthesized capsaicin
241 derivativs on TRPV2 was evaluated in vitro. The assays were
242 conducted using a ﬂuorometric assay with rat TRPV2
243heterologously expressed in HEK-293 cells. The tested
244compounds did not signiﬁcantly activate TRPV2-mediated
245Ca2+ elevation in transfected HEK-293 cells. Instead,
246preincubation (5 min) of TRPV2-HEK-293 cells with diﬀerent
247concentrations of the tested compounds, followed by
248incubation with LPC (3 μM), caused inhibition of intracellular
249Ca2+ elevation due to TRPV2 response to LPC. The
250corresponding IC50 values are reported in Table 1.
251The structure−activity relationships (SARs) of these
252compounds suggested a critical inﬂuence on the capability to
253exert TRPV2 antagonism of the alkyl chain and, in particular,
254of its hydrophobicity, length, and degree of unsaturation.
255Hydrophobicity is important since, as shown in Table 1, the
256activity dramatically dropped after introduction in the chain of
257polar substituents such as hydroxyl, keto, or ester groups
258(these groups arising from esteriﬁcation of the hydroxyl group)
259or their combinations (42, 44, 50, 45, 51, 9, 12, 15). However,
260the presence of an amino group next to the amide (55, 60, 56,
26161), which had marginal eﬀects for already active compounds,
262by only slightly increasing their potency (60 vs 46), was
263instead dramatic for those inactive compounds bearing a
264hydroxyl or an ester moiety in the alkyl chain, whose activity
265was completely rescued (see 42 vs 57). The complete recovery
266of activity after introduction of an amino group next to the
267amide in derivatives bearing a polar substituent in the alkyl
268chain suggests that reinforcement of the polar interactions of
269the “head” avoids the competition with the polar-substituted
270alkyl chain for interaction with receptor polar residues in a
271region where the polar head, but not the alkyl chain, should be
272hosted to elicit a measurable eﬀect. The chain is fairly more
273tolerant to changes not substantially aﬀecting the hydro-
274phobicity of the alkyl group: replacement of sulfur with
275selenium in the alkyl chain did not aﬀect signiﬁcantly ligand
276activity (39 vs 46); its replacement with a carbon atom
277determined an increase in potency (64 vs 40/47). While polar
278functionalization of the alkyl chain caused a dramatic drop of
279activity, amino or imino groups (67, 73) were well tolerated in
280the region close to the amide moiety of capsaicin. In particular,
281the imino derivatives were among the most active compounds
282within the series (IC50 = 0.28 and 0.12 μM, respectively). Also
283length and unsaturation degree of the alkyl chain signiﬁcantly
284aﬀected the activities of the tested compounds. The C16:0 and
285C18:0 saturated analogs were inactive, whereas the C20:0
286derivative showed an IC50 = 3.1 μM. The insertion of a single
287double bond in C18 chain (olvanil) dramatically increased the
288antagonism, with IC50 = 0.16 μM.
289Thus, the screening led to the identiﬁcation of several very
290potent TRPV2 antagonists, exhibiting IC50 values in the
291subnanomolar to low-micromolar range. This result is quite
292remarkable since, despite its close homology to TRPV1,
293TRPV2 is insensitive to capsaicin, the residues being
294responsible for capsacin binding and receptor activation in
295TRPV1 not conserved in TRPV2.58
296The most striking result from the SAR of capsaicin derivativs
297against LPC is that the elongation of the alkyl chain of
298capsaicin causes a switch of such scaﬀold from inactivity
299toward potent antagonism at rat recombinant TRPV2.
300Intriguingly, the dependence of TRPV2 modulation on the
301length of the ligand alkyl chain has already been observed for
302lysophospholipids, which require a carbon chain longer than
303C12 to stimulate the receptor.21
3042.2.3. Capsaicin Derivatives Inhibit TRPV2 Channels
305 f2Activated by CBD. Due to diﬀerent latency in the activation
Figure 1. Chemical structure of capsaicin. The vanillyl head, the
amide neck, and hydrophobic tail are shaded in yellow, cyan, and gray,
respectively.
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Table 1. Antagonist Potency of Capsaicin-like Compounds at TRPV2 against LPC (3 μM) and CBD (2 μM), Reported as IC50
(μM)
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f2 306 proﬁle between LPC and cannabidiol (CBD) (see Figure 2),
307 we also investigated the eﬀect of a representative panel of
308 capsaicin derivatives against CBD to ascertain whether the
309 inhibitory activity/potency would vary against agonists
310 exhibiting diﬀerent kinetics of action. Also in this case, the
311 assays were conducted using a ﬂuorometric assay with
312 recombinant rat TRPV2 heterologously expressed HEK-293
313 cells. The preincubation (5 min) of TRPV2-HEK-293 cells
314 with diﬀerent concentrations of the tested compounds,
315 followed by incubation with CBD (2 μM), caused an
316 inhibition of the Ca2+ elevation due to the TRPV2 response
317 to CBD. The corresponding IC50 values of the tested
318 compounds are reported in Table 1. While the trend identiﬁed
319 in LPC antagonism for capsaicin derivatives bearing all carbon
320 atoms, selenium, or sulfur was substantially conserved, a
321diﬀerent behavior was observed with those derivatives
322featuring polar substituents (i.e., 50/51), since their activity
323against CBD was not negatively aﬀected by these functional
324groups, as instead observed against LPC. The imino-derivatives
32567 and 73 (see Table 2), i.e., the two most active compounds
326against LPC (0.28 and 0.12 μM, respectively), were less potent
327against CBD (IC50 = 6.0 and 3.0 μM, respectively). The trend
328of activity of C16:0, C18:0, and C18:1 derivatives was similar
329to that observed for LPC, although C18:1 (olvanil) was less
330potent as an antagonist (IC50 = 1.7 μM), whereas, diﬀerent
331from what observed with LPC, C20:0 was totally inactive.
332These results demonstrate a dependence of the antagonist
333activity on the type of agonist against which antagonism is
334tested.
Table 1. continued
aIn parentheses, number of C atoms in the alkyl chain followed by number of unsaturations. When heteroatom X occurs within alkyl chain, it is
indicated as “/X”. bnd: not determined.
Table 2. Antagonist Potency of Capsaicin-Imino Compounds at TRPV2 against LPC (3 μM) and CBD (2 μM), Reported as
IC50 (μM)
a
aIn parentheses, number of C atoms in the alkyl chain followed by number of unsaturations.
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335 2.2.4. Evaluation of Endogenous Lipids as Potential
336 TRPV2 Antagonists. Since the activity of the tested
337 compounds appears to critically depend on the nature of
338 alkyl chain but is less aﬀected by changes in the polar head, we
339decided to ascertain the role of the head group of capsaicin,
340i.e., the vanillyl moiety, by testing a series of naturally occurring
341lipids bearing diﬀerent polar heads and diﬀering in length and
342unsaturation of the alkyl chain in order to determine the
343structural and functional requisites for TRPV2 modulation.
3442.2.5. Long-Chain Ethanolamides Exhibit Diﬀerential
345Inhibition of TRPV2 upon Activation by LPC or CBD. To
346evaluate the contribution of the aromatic moiety to the overall
347activity, a panel of natural occurring ethanolamides diﬀering in
348length and unsaturation degree was tested for both agonism
349and antagonism at TRPV2, using both LPC and CBD as
350reference activators. Ethanolamides share with the tested
351capsaicin derivativs the nature of both the alkyl chain and the
352hydrophilic groups (amide and hydroxyl moieties) in the polar
353head. The IC50 values (against CBD 2 μM and LPC 3 μM) are
354 t3reported in Table 3. Ethanolamides featuring saturated alkyl
355chains, regardless of their lengths, were inactive against both
356agonists, whereas the introduction of a single double bond was
357suﬃcient to switch from inactivity to activity against both
358agonists (see PEA vs POEA, or SEA vs OEA), similar to what
359was already observed for capsaicin derivativs. However, while
360the C20:0 capsaicin derivative was active against LPC, the
361homolog ethanolamide was inactive. Moreover, while OEA was
362less active than the counterpart olvanil, LEA was more potent
363than livanil against both reference agonists. Increasing the
Figure 2. TRPV2 is activated by LPC (3 μM) and CBD (2 μM). The
graph shows the representative traces of [Ca2+]i increase evoked by
the two agonists in HEK293 cells overexpressing TRPV2.
Table 3. Potency of Fatty Ethanolamides as Functional Antagonists at TRPV2 against LPC (3 μM) and CBD (2 μM), Reported
as IC50 (μM)
aAbbreviations: EA, ethanolamide; PEA, palmitoyl ethanolamide; POEA, palmitoleoyl ethanolamide; OEA, oleoyl ethanolamide; LEA, lynoleoyl
ethanolamide; arachidonoylethanolamide; EPEA, eicosapentaenoyl ethanolamide; DHEA, docosahexaenoyl ethanolamide. bIn parentheses,
number of C atoms in the alkyl chain followed by number of unsaturations.
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364 number of double bonds increased the potency against CBD
365 but not LPC.
366 2.2.6. Long-Chain Primary Amides Exhibit Diﬀer-
367 ential Inhibition of TRPV2 Channels upon Activation by
368 LPC or CBD. To also evaluate the role of the hydroxyl group,
369 we tested a series of amide derivatives. As for capsaicin- and
370 ethanolamine-derivatives, also for the amides the activity
371 strongly depended upon the presence of at least one double
372 bond. In particular, erucamide is active as TRPV2 antagonist
373 with a potency comparable to that of its capsaicin derivative
374(0.67 vs 0.49 μM) against LPC, but it is less potent than the
375capsaicin counterpart against CBD (7.1 vs 1.5 μM). As
376observed with the ethanolamides, also the C20:0 amide
377 t4derivative was inactive against both activators (Table 4).
3782.2.7. Free Fatty Acids Are Poor Inhibitors of TRPV2
379Channels. Finally, to investigate the role of the amide group,
380we tested against both LPC and CBD a panel of long-chain
381fatty acids, featuring alkyl chains comparable with those
382occurring in the already-tested compounds. The results are
383 t5reported in Table 5. Fatty acids with alkyl chains from C16 up
Table 4. Antagonist Potency of Fatty Amides at TRPV2 against LPC (3 μM) and CBD (2 μM), Reported as IC50 (μM)
aAbbreviations: PA, palmitamide; SA, stearamide; OA, oleamide; LA, linoleamide; ErA, erucamide. bIn parentheses, number of C atoms in the alkyl
chain followed by number of unsaturations.
Table 5. Lack of Strong Antagonist Activity of Fatty Acids at TRPV2 against LPC (3 μM) and CBD (2 μM), Reported as IC50
Values (μM)
aIn parentheses, number of C atoms in the alkyl chain followed by number of unsaturations.
Table 6. Slope Values from Linear Regression of Schild Analysis and t-Test Statistics
LPC CBD
compd slopea Nb Pc slopea Nb Pc
61 −0.58 ± 0.087 4 <0.0024 −0.74 ± 0.048 4 <0.002
olvanil −0.77 ± 0.049 6 <0.001 −0.55 ± 0.068 6 <0.001
docosaenoyl-EA −0.54 ± 0.046 6 <0.001
50 −0.63 ± 0.039 5 <0.001
aMean value ± standard deviation. bNumber of experiments (each one performed at least in triplicate) used for Schild regression. cP values
calculated from t test values for the “slope = 1 hypothesis”.
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384 to C22 are by far less potent antagonists against both reference
385 agonists than the other classes of compounds bearing similar
386 alkyl chains, thus suggesting that the amide group is mandatory
387 for potent antagonism.
388 2.2.8. Schild Analysis on Selected TRPV2 Antagonists.
389 The eﬀects of increasing concentrations of antagonist 61,
390 olvanil, and docosaenoyl-EA vs LPC and 61, olvanil, and 50 vs
391 CBD were tested against concentration−response curves of
392 LPC and CBD (where the eﬀects of each concentration of
393 LPC and CBD were expressed as percent of their eﬀect of 2 ×
394 10−4 M in the absence of the antagonist) to calculate Schild’s
395 plots. These compounds have been selected as representative
396 of antagonists active either against both activators (61, olvanil)
397 or selectively toward LPC (docosaenoyl-EA)/CBD (50) alone.
398 In all cases, the plots analyzed by linear regression gave slope
t6 399 values signiﬁcantly less than unity, as reported in Table 6,
400 indicative of a noncompetitive behavior. However, this result
401 may also be indicative of a nonequilibrium condition, and we
402 do not deﬁnitely rule out a competitive behavior.
3. DISCUSSION
403 Novel capsaicin derivativs, initially designed as TRPV1
404 agonists, behave as potent TRPV2 antagonists. The diﬀerent
405 types of modiﬁcations introduced in these compounds
406 determine diﬀerent agonist/antagonist proﬁles and, in
407 particular, opposite behaviors in terms of relative potency/
408 eﬃcacy within a derivative series on the two channels. In fact,
409 the insertion of a positive charge or an imido group close the
410 amido group, detrimental for TRPV1 agonism, is well-tolerated
411 for TRPV2 antagonism and even leads in some cases to an
412 increment or a rescue of activity. Conversely, the insertion of a
413 sulfur/selenium atom and/or the presence of a polar group,
414 which increases TRPV1 agonism, leaves unaﬀected, or even
415 decrease, TRPV2 antagonism.
416 Given the scarcity of known endogenous ligands for TRPV2,
417 the discovery of such long-chain capsaicin derivativs as potent
418 TRPV2 antagonists prompted us to investigate the following
419 classes of long-chain fatty acid derivatives with at least one
420 functional group in common with capsaicin derivatives as
421 potential TRPV2 modulators: (i) ethanolamides, (ii) primary
422 amides, and (iii) free fatty acids, to evaluate the role of the
423 amide group itself. Antagonists were found in both the
424 ethanolamide and primary amide, but not in fatty acid, series.
425 Activities for both synthetic and endogenous ligands were
426 tested against either LPC or CBD as activators, since, on the
427 basis of their diﬀerent kinetics of activation, CBD can be
428 deﬁned as a direct TRPV2 agonist, whereas LPC induces
429 TRPV2 activation indirectly, via its G-protein-coupled
430 receptors and PI3,4 kinase mediated pathways.21 We found
431 that this diﬀerent mode of activation is diﬀerentially counter-
432 acted by the investigated compounds, which can be classiﬁed
433 as follows: (a) compounds endowed with similar antagonist
434 eﬃcacy against both agonists, (b) compounds selectively active
435 against LPC, (c) compounds selectively active against CBD.
436 To determine the nature of antagonism, a Schild regression
437 was carried out for the representative members of each class,
438 i.e., olvanil, docoesanoyl-EA, and compound 50, and in all
439 three cases the antagonists behaved as noncompetitive ligands,
440 suggesting that these compounds may act as allosteric
441 antagonists. However, we cannot completely rule out a
442 competitive behavior since a Schild plot slope of <1 may
443 also suggest nonequilibrium conditions. Moreover, since the
444 hydrophobicity of the alkyl chain of the investigated
445compounds is a critical requisite for LPC but not for CBD
446inhibition, it is reasonable to speculate that a diﬀerent binding
447site is involved in LPC antagonism, with structural/functional
448requisites diﬀerent from those of CBD. This site might be
449either on TRPV2 or on other targets activated by LPC in its
450signaling cascade and would be the target of those compounds
451selectively antagonizing activation by LPC. A common critical
452requisite for activity of both ethanolamides and amides as
453TRPV2 antagonists is the occurrence of at least one double
454bond in the alkyl chain, since saturated lipids, regardless of the
455length of their acyl chains, are totally inactive. This suggests
456that a bent conformation of the alkyl chain is required for a
457better accommodation into the active site, as previously
458reported for other TRPV1 agonists.59 Also C16:0 and C18:0
459derivatives of capsaicin are inactive against both CBD and
460LPC, whereas the C20:0 derivative is selectively active against
461LPC. Instead, a diﬀerent behavior is observed with imino-
462capsaicin derivatives since they are active also when bearing
463saturated alkyl chain. The aromatic moiety contributes to the
464overall activity at TRPV2 of the compounds characterized in
465the present work, since it occurs in the most active antagonists.
4. CONCLUSIONS
466In summary, the search for structurally related synthetic or
467endogenous lipids with structural similarity to capsaicin
468derivativs led to identiﬁcation of olvanil and 73 as potent
469TRPV2 antagonists against LPC (0.16 and 0.12 μM,
470respectively) and of LEA (linoleoylethanolamide) as potent
471TRPV2 antagonist against CBD (0.65 μM). This ﬁnding is
472both surprising, since all other synthetic and endogenous
473compounds tested here on TRPV2 behave as antagonists and
474capsaicin is inactive at this channel, and of great physiological
475importance, since novel potent endogenous antagonists were
476been identiﬁed following this study.
477In conclusion, starting from the testing of a series of
478synthetic capsaicinoids as modulators of rat TRPV2, we
479discovered not only new tools for the pharmacological
480manipulation of the latter but also that previously described
481endogenous lipids, i.e., long chain fatty acid ethanolamides and
482primary amides, behave as negative modulators of this channel.
483These data are of great potential importance given the
484increasingly important role assigned to TRPV2 in temperature
485sensing, pain, insulin secretion, immune response, muscle and
486heart function, and cancer.58
5. EXPERIMENTAL SECTION
4875.1. Compounds. Stevanil, livanil, ethanolamides, amides, and
488fatty acids when not described in the synthetic section have been
489purchased from Cayman-Vinci Biochem. Palvanil and PEA are kind
490gifts from Epitech Group SpA, Saccolongo, Padova, Italy, whereas
491olvanil is a precious gift from Dr. Alberto Minassi, Dipartimento di
492Scienze del Farmaco, Universita ̀ del Piemonte Orientale, Novara,
493Italy.
4945.2. Synthetic Procedures. Reactions requiring anhydrous
495conditions were performed in blazed or oven-dried glassware using
496anhydrous solvents and under inert atmosphere (argon). The solvents
497and reagents were purchase from Acros Organics, Sigma-Aldrich,
498Fluka, Merk, Panreac, Strem Chemicals, or TCI Chemicals.
499Petroleum ether, EtOAc, DCM, and MeOH were used without
500further puriﬁcation. In the case of anhydrous reactions, solvent and
501reagents were properly dried. Acrolein was distilled at atmospheric
502pressure and used immediately. The reactions were monitored until
503completion by TLC on silica gel 60F-254 precoated plates (Merck).
504Visualization of the compounds was performed by UV light (254 nm),
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505 and staining was performed by immersion in a 5% solution of
506 concentrated H2SO4 in methanol or 5% w/v phosphomolibdic acid in
507 ethanol followed by heating. Flash column chromatography was
508 performed using silica gel (technical grade, 60 Å, 40−63 μm) (Sigma-
509 Aldrich) under air pressure. NMR spectra were recorded on a
510 MERCURYplus AS400 MHz Varian spectrometer. Chemical shifts
511 are reported in parts per million (ppm, δ units). Coupling constants
512 (J) are reported and expressed in hertz (Hz). Ssplitting patterns are
513 designated as br (broad), s (singlet), d (doublet), dd (double
514 doublet), t (triplet), q (quartet), dt (double triplet), td (triple
515 doublet), ddd (double double doublet), p (pentuplet), and m
516 (multiplet). All 13C NMR spectra were proton decoupled. High
517 resolution mass spectra (HR-MS) were recorded on at the Serveis
518 Cientiﬁcotec̀nics of Universitat de Lleida (SCT-UdL) and Servei de
519 Recursos Cientiﬁ́cs i Tec̀nics of Universitat Rovira i Virgili (URV)
520 with an Agilent G6510AA Q-TOF MS spectrometer in positive
521 electrospray ionization (ESI+) and Agilent LC1200 series coupled to
522 MS6210 TOF spectrometer in electrospray ionization (ESI+)
523 respectively. Mobile phase was composed of ACN/MeOH 50:50.
524 Flow rate: 0.6 mL/min. Infrared spectra were recorded on Jasco FT-
525 IR 6300 using a diamond ATR crystal cell. Melting points were
526 measured using Gallenkamp capillary apparatus and are uncorrected.
527 Optical rotations were measured at 20 °C with a PerkinElmer 241 nc
528 polarimeter (λ = 589 Na, path length 1 dm). Some recorded values
529 were within the error limit of the polarimeter, and therefore it was not
530 possible to determine them. It has been indicated as [α]D
20 < 1°.
531 Analytical UPLC−MS was performed on a binary Acquity UPLC with
532 a Acquity PDA UPLC eLambda 800 nm triple quadrupole mass
533 spectrometer (Xevo TQ-S) using a Acquity UPLC BEH C18 50 × 2.1
534 mm, 1.7 μm C18 column. UV detection = 210−500 nm, mass
535 spectrometry= ESI+ (scan 100−850 m/z). Flow rate was 0.3 mL/min
536 using a solvent gradient of B 100% over 6 min (total run time with
537 equilibration back to starting conditions = 2 min) where A = MeOH
538 and B = 85/15/0.2 MeOH/H2O/AcOH. Purities were measured by
539 UV absorption at 254 nm or TIC and are ≥95% unless otherwise
540 stated. Purity of ﬁnal compounds was assessed by reversed-phase
541 UHPLC with UV diode array detection; all tested compounds were
542 >95% pure.
543 5.2.1. Procedure I. Amine Bond Formation. To a 0.35 M
544 solution of starting material in anhydrous DMF were added the amine
545 3 (1.1 equiv), HATU (1.5 equiv), and DIPEA (3 equiv). The mixture
546 was stirred at room temperature for 20 h. To the mixture were added
547 EtOAc and brine, and the aqueous phase was extracted with EtOAc.
548 The combined organic phases were washed with 1 M HCl, saturated
549 solution of NaHCO3 and brine. The organic phase was dried over
550 anhydrous Na2SO4, ﬁltered and the solvent was removed under
551 reduced pressure. The crude residue was puriﬁed by silica gel column
552 chromatography.
553 5.2.2. Procedure II. Ester Hydrolysis. To a 0.2 M solution of
554 starting material in THF/H2O (1:1) LiOH·H2O (3 equiv) was added.
555 The mixture was stirred at room temperature until completion of the
556 reaction. The reaction mixture was acidiﬁed with 1 M HCl until pH 1
557 and extracted with EtOAc. The organic phase was dried over
558 anhydrous Na2SO4, ﬁltered, and the solvent was removed under
559 reduced pressure to aﬀord the corresponding compound.
560 5.2.3. Procedure III. Boc Protection. Et3N (1.5 equiv) was
561 added to a 0.3 M aqueous solution of starting material, cooled in an
562 ice bath. Then Boc2O (1.5 equiv) was added dropwise and stirred
563 overnight. After completion of the reaction, the solvent was
564 evaporated under reduced pressure. The residue was dissolved in
565 EtOAc, washed with 1 M HCl and brine, dried over anhydrous
566 Na2SO4, ﬁltered, and evaporated under reduced pressure. The crude
567 residue was thoroughly washed with hexane several times.
568 5.2.4. Procedure IV. SS/SeSe Bond Cleavage. SS Bond
569 Cleavage. To a 0.15 M solution of starting material in wet THF
570 was added tri-n-butylphosphine (P(nBu)3) (1.05 equiv). The reaction
571 mixture was stirred at room temperature for 2 h. After completion of
572 the reaction, the solvent was removed under reduced pressure to
573 aﬀord the crude product, which was puriﬁed by silica gel column
574 chromatography.
575SeSe Bond Cleavage and Se-Alkylation. To a 0.13 M solution of
576starting material in ethanol was added NaBH4 (2.5 equiv) at 0 °C.
577The reaction mixture was stirred for 20 min, followed by addition of
578the respective iodinated compound. The reaction mixture was stirred
579at room temperature for 16 h. Then, the reaction was quenched with
5801 M HCl and extracted with EtOAc. The organic phase was dried
581over anhydrous Na2SO4, ﬁltered, and the solvent was removed under
582reduced pressure. The crude residue was puriﬁed by silica gel column
583chromatography.
5845.2.5. Procedure V. Reduction of Methyl Ester. To a 0.2 M
585solution of starting material in anhydrous THF, LiAlH4 (2 equiv) was
586added at 0 °C. The reaction mixture was stirred at room temperature
587for 24 h. Then, the reaction was quenched with 1 M HCl, followed by
588extraction with DCM. The combined organic phases were dried over
589anhydrous Na2SO4, ﬁltered, and the solvent was removed under
590reduced pressure. The solid residue was puriﬁed by silica gel column
591chromatography.
5925.2.6. Procedure VI. Iodination. To a 0.25 M solution of starting
593material in toluene iodine (1.2 equiv), imidazole (3 equiv) and PPh3
594(1.2 equiv) were added. The mixture was stirred at 90 °C for 2 h. The
595solvent was evaporated under reduced pressure. The residue was
596dissolved in EtOAc, washed with saturated aqueous solution of
597KMnO4, water, and brine, dried over anhydrous Na2SO4, ﬁltered, and
598evaporated under reduced pressure. The solid residue was puriﬁed by
599silica gel column chromatography.
6005.2.7. Procedure VII. S-Alkylation. To a 0.2 M solution of
601starting material in DMF, TEA (1.5 equiv) and the corresponding
602iodinated compound (1.12 equiv) were added. The reaction mixture
603was stirred at 90 °C overnight. To the mixture were added EtOAc and
604brine, and the aqueous phase was extracted with EtOAc. The
605combined organic phases were washed with 1 M HCl, saturated
606solution of NaHCO3, and brine. The organic phase was dried over
607anhydrous Na2SO4, ﬁltered, and the solvent was removed under
608reduced pressure. The crude residue was puriﬁed by silica gel column
609chromatography.
6105.2.8. Procedure VIII. TBDMS Deprotection. A 0.25 M solution
611of the starting material in a mixture of AcOH/THF/H2O was stirred
612at room temperature until deprotection was complete. The solvent
613was evaporated under reduced pressure to obtain the reaction crude,
614which was puriﬁed by silica gel column chromatography.
6155.2.9. Procedure IX. Boc Deprotection. To a 0.3 M solution of
616starting material in DCM, TFA (10 equiv) was added. The reaction
617mixture was stirred for 1 h, followed by removal of the solvent under
618nitrogen stream and drying in vacuo to aﬀord the triﬂuoroacetate salt
619of the compound.
6205.2.10. Procedure X. Base Schiﬀ Formation. To a 0.03 M
621solution of starting material in MeOH, vanillin 1 (1 equiv) was added.
622The mixture was reﬂuxed for 2 h in the presence of small amount of
623glacial AcOH. After cooling, the reaction mixture was ﬁltered to
624recover a solid, which was recrystallized from hot MeOH to aﬀord the
625 gcorresponding compound.
626(E)-4-Hydroxy-3-methoxybenzaldehyde Oxime (2). Hydrox-
627ylamine hydrochloride (2.37 g, 34.0 mmol) in H2O (10 mL) and
628sodium acetate trihydrate (4.48 g, 32.9 mmol) in H2O (10 mL) were
629successively added to a solution of vanillin 1 (5.00 g, 32.9 mmol) in
630H2O (30 mL). The reaction mixture was stirred at 80 °C for 2 h. The
631reaction mixture was extracted with EtOAc, and the organic layer was
632dried over anhydrous Na2SO4 and ﬁltered. The solvent was
633evaporated under reduced pressure to yield the oxime 21 (5.26 g,
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b00734
J. Med. Chem. XXXX, XXX, XXX−XXX
K
634 97%) as an oﬀ-white solid. Mp = 118−119 °C. IR (ATR) ν = 3444,
635 3213, 3008, 2941, 1596, 1513, 1428, 1027, 969 cm−1. 1H NMR (400
636 MHz, (CD3)2SO) δ = 3.77 (s, 3H, CH3O), 6.77 (d, 1H, J = 8.1 Hz,
637 HAr), 6.97 (dd, 1H, J = 8.1, 2.0 Hz, HAr), 7.16 (d, 1H, J = 2.0 Hz,
638 HAr), 7.99 (s, 1H, CHN), 9.33 (s, 1H, OH), 10.84 (s, 1H, N-OH).
639
13C NMR (101 MHz, (CD3)2SO) δ = 55.50 (CH3O), 109.21 (CAr),
640 115.49 (CAr), 120.52 (CAr), 124.47 (CCHN), 147.85 (COH), 148.01
641 (CCH3O), 148.10 (CHN).
642 4-Hydroxy-3-methoxybenzylamine Hydrochloride (3). 37%
643 HCl (20 mL, 0.26 mol) and Pd/C (10 wt % loading) (20% w/w, 1.05
644 g) were added to a solution of 2 (5.2 g, 0.03 mol) in EtOH (150 mL).
645 The reaction mixture was hydrogenated at 1 atm at room temperature
646 for 24 h. The reaction mixture was ﬁltered over Celite, and the solvent
647 volume was reduced under pressure. The residue was crystallized from
648 EtOAc and ﬁltered to yield the amine hydrochloride salt 32 (4.2 g,
649 74%) as a white solid. Mp = 219−222 °C. IR (ATR) ν = 3112, 3024,
650 2805, 1763, 1377, 1033, 828, 670 cm−1. 1H NMR (400 MHz,
651 (CD3)2SO) δ = 3.77 (s, 3H, CH3O), 3.83−3.90 (m, 2H, CH2NH2),
652 6.79 (d, 1H, J = 8.1 Hz, HAr), 6.85 (dd, 1H, J = 8.1, 2.0 Hz, HAr), 7.18
653 (d, 1H, J = 2.0 Hz, HAr), 8.40 (br, s, 3H, NH2, HCl), 9.19 (s, 1H,
654 OH). 13C NMR (101 MHz, (CD3)2SO) δ = 42.19 (CH2NH2), 55.70
655 (CH3O), 113.45 (CAr), 115.27 (CAr), 121.74 (CAr), 124.64 (CCHN),
g 656 146.81 (COH), 147.51 (CCH3O).
657 Methyl 12-Oxooctadec-(10E)-enoate (5). Shvo’s catalyst (9
658 mg, 8 μmol) and acrolein freshly distilled (390 μL, 4.80 mmol) were
659 added to a solution of methyl ricinoleate 4 (500 mg, 1.60 mmol) in
660 anhydrous toluene (15 mL). The reaction mixture was purged with
661 N2 and stirred under reﬂux for 45 min. The solvent was evaporated
662 under reduced pressure, and after the puriﬁcation by silica gel column
663 chromatography (petroleum ether/Et2O 95:5) the enone 5
3 (348 mg,
664 70%) was obtained as a yellowish oil. Rf = 0.50 (petroleum ether/
665 Et2O 9:1). IR (ATR) ν = 2927, 2855, 1736, 1709, 1436, 1195, 1169,
666 1104, 979, 880, 752 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.86 (t,
667 3H, J = 6.9 Hz, CH3), 1.23−1.33 (m, 14H, CH2), 1.38−1.48 (m, 2H,
668 CH2), 1.52−1.65 (m, 4H, CH2), 2.18 (q, 2H, J = 6.4 Hz, CH2), 2.29
669 (t, 2H, J = 6.9 Hz, CH2), 2.51 (t, 2H, J = 6.9 Hz, COCH2), 3.65 (s,
670 3H, CH3O), 6.07 (dt, 1H, J = 15.9, 1.5 Hz, CHCH), 6.80 (dt, 1H, J
671 = 15.9, 6.9 Hz, CHCH). 13C NMR (101 MHz, CDCl3) δ = 14.01
672 (CH3), 22.48 (CH2), 24.27 (CH2), 24.86 (CH2), 28.04 (CH2), 28.96
673 (CH2), 29.07 (4 × CH2), 31.59 (CH2), 32.38 (CH2), 34.02 (CH2),
674 40.08 (COCH2), 51.41 (CH3O), 130.28 (CHCH), 147.20 (CH
g 675 CH), 174.24 (COO-), 200.99 (COCH2).
676 Methyl 12-Oxo-10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
677 2-yl)octadecanoate (6). Tri-n-butylphosphine (26 μL, 0.10 mmol)
678 was added to a solution of anhydrous CuCl (10 mg, 0.10 mmol) in
679 anhydrous DMF (4.5 mL) under argon atmosphere. In another
680 reaction vessel, bis(pinacolato)diboron (283 mg, 1.12 mmol) was
681 added to a solution of methyl 12-oxooctadec-(10E)-enoate 5 (290
682 mg, 0.93 mmol) in anhydrous DMF (4.5 mL) under argon
683atmosphere. This solution was transferred to the tri-n-butylphosphine
684solution. The reaction mixture was stirred at room temperature for 48
685h. The crude was taken up in H2O and extracted with petroleum
686ether. The organic solution was dried over anhydrous Na2SO4, ﬁltered
687and the solvent was evaporated under reduced pressure to yield the β-
688boron ketone 6 (190 mg, 46%) as a yellow oil after the puriﬁcation by
689silica gel column chromatography (petroleum ether/EtOAc 95:5). Rf
690= 0.49 (petroleum ether/Et2O 9:1).
1H NMR (400 MHz, CDCl3) δ =
6910.84 (t, 3H, J = 6.9 Hz, CH3), 1.18−1.28 (m, 30H, (CH3)4, CH2),
6921.34−1.39 (m, 1H, CHB), 1.49−1.60 (m, 4H, CH2), 2.27 (t, 2H, J =
6936.9 Hz, CH2), 2.33 (td, 2H, J = 7.4, 3.7 Hz, COCH2), 2.50 (d, 2H, J =
6946.8 Hz, CHBCH2CO), 3.64 (s, 3H, CH3O).
69512-Oxo-10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
696octadecanoic Acid (7). Novozym 435 (83 mg, 50% w/w) was
697added to a solution of the methyl ester 6 (190 mg, 0.43 mmol) in a
698mixture of H2O (308 μL) and tert-BuOH (922 μL). The reaction
699mixture was stirred at 45 °C for 24 h. The mixture was ﬁltered and the
700solvent was evaporated under reduced pressure to yield the acid 7
701(180 mg, quantitative) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ
702= 0.87 (t, 3H, J = 6.9 Hz, CH3), 1.20−1.34 (m, 30H, (CH3)4, CH2),
7031.38−1.44 (m, 1H, CHB), 1.51−1.58 (m, 2H, CH2), 1.59−1.66 (m,




708procedure I was applied to a solution of the acid 7 (175 mg, 0.41
709mmol) dissolved in anhydrous DMF (6 mL), amine hydrochloride
710salt 3 (69 mg, 0.45 mmol), DIPEA (200 μL, 1.24 mmol), and HATU
711(235 mg, 0.62 mmol). The amide 8 was obtained (125 mg, 54%) as a
712brown oil after the puriﬁcation by silica gel ﬂash column
713chromatography (petroleum ether/EtOAc 6:4). Rf = 0.55 (petroleum
714ether/EtOAc 3:7). 1H NMR (400 MHz, CDCl3) δ = 0.87 (t, 3H, J =
7156.7 Hz, CH3), 1.21−1.31 (m, 30H, (CH3)4, CH2), 1.35−1.41 (m, 1H,
716CHB), 1.52−1.57 (m, 2H, CH2), 1.61−1.67 (m, 2H, CH2), 2.18 (t,
7172H, J = 6.9 Hz, CH2), 2.32−2.39 (m, 2H, COCH2), 2.52 (d, 2H, J =
7186.7 Hz, CHBCH2CO), 3.88 (s, 3H, CH3O), 4.35 (d, 2H, J = 5.6 Hz,
719CH2NH), 5.64−5.71 (m, 1H, CH2NH), 6.82 (ddd, 3H, J = 12.5, 9.9,
720 g5.5 Hz, HAr).
721N-(4′-Hydroxy-3′-methoxybenzyl)-10-hydroxy-12-oxoocta-
722decanamide (9). A volume of 5% w/v NaHCO3 (2.5 mL, 1.49
723mmol) was added to a solution of compound 8 (125 mg, 0.22 mmol)
724and 2.5 mL of 30% H2O2 (0.02 mmol). The reaction mixture was
725stirred at room temperature for 24 h. Saturated aqueous Na2S2O4
726(0.25 mL) was added to decompose any remaining peroxide keeping
727the temperature below 40 °C. The reaction mixture was diluted with
728H2O and extracted with EtOAc. The organic solution was dried over
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729 anhydrous Na2SO4 and ﬁltered. The solvent was evaporated under
730 reduced pressure to yield the β-hydroxy ketone 9 (75 mg, 76%) as a
731 rosaceous solid after the recrystallization from Et2O. Mp = 73−75 °C.
732 IR (ATR) ν = 3318, 2912, 2849, 1705, 1638, 1513, 1267, 1240, 1122,
733 718 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.88 (t, 3H, J = 6.9, Hz,
734 CH3), 1.20−1.41 (m, 18H, CH2), 1.40−1.50 (m, 2H, CH2), 1.52−
735 1.60 (m, 2H, CH2), 1.60−1.68 (m, 2H, CH2), 2.18 (t, 2H, J = 6.9 Hz,
736 CH2), 2.41 (t, 2H, J = 6.9 Hz, COCH2), 2.46−2.52 (m, 1H,
737 CHCH11aCO), 2.59 (dd, 1H, J = 17.3, 1.8 Hz, CHCH11bCO), 3.08
738 (br s, 1H, CHOH), 3.87 (s, 3H, CH3O), 3.94−4.05 (m, 1H, CHOH),
739 4.35 (d, 2H, J = 5.7 Hz, CH2NH), 5.69 (br s, 2H, OH, CH2NH),
740 6.67−6.88 (m, 3H, HAr). 13C NMR (101 MHz, CDCl3) δ = 14.16
741 (CH3), 22.61 (CH2), 23.73 (CH2), 25.53 (CH2), 25.87 (CH2), 28.97
742 (CH2), 29.34 (CH2), 29.35 (CH2), 29.48 (CH2), 29.55 (CH2), 31.70
743 (CH2), 36.52 (CH2), 36.96 (CH2), 43.66 (CH2NH), 43.84
744 (COCH2), 49.06 (CHCH2CO), 56.08 (CH3O), 67.77 (CHOH),
745 110.85 (CAr), 114.53 (CAr), 120.93 (CAr), 130.56 (CAr), 145.25 (CAr),
746 146.84 (CAr), 172.99 (NHCO), 212.84 (COCH2). HR-MS (ESI
+),
g 747 m/z: [M + Na]+ calcd for C26H43NO5Na 472.3033; found 472.3042.
748 Methyl (12R)-Hydroxyoctadec-(9E)-enoate (10). Diphenyl
749 disulﬁde (56 mg, 0.26 mmol) was added to a solution of methyl
750 ricinoleate 4 (4 g, 12.8 mmol) in isooctane (120 mL). The reaction
751 mixture was placed in a photochemical reactor and irradiated for 3 h
752 with a Philips HP(L) 400 W medium-pressure mercury lamp. After
753 irradiation the solvent was removed under reduced pressure and the
754 crude reaction mixture was dissolved in hot petroleum ether (185
755 mL). The ﬁltrate was cooled at −30 °C, and after 48 h a white solid
756 appeared. This solid was quickly ﬁltered and recovered at −30 °C to
757 yield the compound 104 (1.49 g, 37%) as a yellowish oil at room
758 temperature. IR (ATR) ν = 3431, 2924, 2854, 1740, 1435, 1197,
759 1171, 969, 860, 724 cm−1. [α]D
20 −0.2° (c 2.44, CHCl3). 1H NMR
760 (400 MHz, CDCl3) δ = 0.87 (t, 3H, J = 6.9 Hz, CH3), 1.23−1.39 (m,
761 16H, CH2), 1.39−1.48 (m, 3H, CH2), 1.56−1.71 (m, 2H, CH2),
762 1.97−2.09 (m, 3H, CH2, H11a), 2.18−2.26 (m, 1H, H11b), 2.29 (t, 2H,
763 J = 6.9 Hz, CH2), 3.53−3.61 (m, 1H, CHOH), 3.65 (s, 3H, CH3O),
764 5.47−5.56 (m, 1H, CHCH), 5.47−5.56 (m, 1H, CHCH). 13C NMR
765 (101 MHz, CDCl3) δ = 14.22 (CH3), 22.75 (CH2), 25.05 (CH2),
766 25.79 (CH2), 29.06 (CH2), 29.20 (CH2), 29.22 (CH2), 29.49 (2 ×
767 CH2), 31.97 (CH2), 32.75 (CH2), 34.22 (CH2), 36.88 (CH2), 40.85
768 (CHCH2CHO), 51.57 (CH3O), 71.06 (CHOH), 126.07 (CHCH),
g 769 134.69 (CHCH), 174.44 (COO-).
770 (12R)-Hydroxyoctadec-(9E)-enoic Acid (11). General proce-
771 dure II was applied to a solution of compound 10 (200 mg, 0.64
772 mmol) dissolved in THF/H2O (3 mL, 1:1) and LiOH·H2O (46 mg,
773 1.92 mmol) to yield the fatty acid 115 (150 mg, 78%) as a yellowish
774 solid after a recrystallization in hot petroleum ether. Mp = 49−51 °C.
775 [α]D
20 +6.6° (c 1, EtOH). IR (ATR) ν = 3321, 3221, 3040, 2955, 2916,
776 2848, 1690, 1466, 1072, 959, 720, 682 cm−1. 1H NMR (400 MHz,
777 CDCl3) δ = 0.88 (t, 3H, J = 6.9 Hz, CH3), 1.22−1.40 (m, 16H, CH2),
778 1.40−1.50 (m, 4H, CH2), 1.58−1.68 (m, 2H, CH2), 1.97−2.11 (m,
779 3H, CH2, H11a), 2.18−2.28 (m, 1H, H11b), 2.33 (t, 2H, J = 6.9 Hz,
780 CH2), 3.54−3.63 (m, 1H, CHOH), 5.33−5.46 (m, 1H, CHCH),
781 5.45−5.58 (m, 1H, CHCH). 13C NMR (101 MHz, CDCl3) δ = 14.24
782 (CH3), 22.77 (CH2), 24.79 (CH2), 25.79 (CH2), 29.02 (CH2), 29.11
783 (CH2), 29.15 (CH2), 29.47 (CH2), 29.50 (CH2), 31.98 (CH2), 32.73
784 (CH2), 34.06 (CH2), 36.86 (CH2), 40.81 (CHCH2CHO), 71.17
785 (CHOH), 126.05 (CHCH), 134.74 (CHCH), 179.27 (COOH). HR-
786 gMS (ESI+), m/z: [M + Na]+ calcd for C18H34O3Na 321.240; found
787 g321.2411.
788N-(4′-Hydroxy-3′-methoxybenzyl)-(12R)-hydroxyoctadec-
789(9E)-enamide (12). General procedure I was applied to a solution of
790the acid 11 (70 mg, 0.23 mmol) dissolved in anhydrous DMF (3.3
791mL), amine hydrochloride salt 3 (53 mg, 0.28 mmol), DIPEA (122
792μL, 0.70 mmol), and HATU (133 mg, 0.35 mmol). The compound
79312 was aﬀorded (35 mg, 34%) as an oﬀ-white solid after the
794puriﬁcation by silica gel ﬂash column chromatography (petroleum
795ether/EtOAc 6:4). [α]D
20 <+1° (c 0.5, DCM). Rf = 0.37 (petroleum
796ether/EtOAc 6:4). Mp = 73−75 °C. IR (ATR) ν = 3295, 2920, 2849,
7971631, 1515, 1463, 1270, 1030, 959 cm−1. 1H NMR (400 MHz,
798CDCl3) δ = 0.88 (t, 3H, J = 6.9 Hz, CH3), 1.23−1.36 (m, 15H, CH2,
799H13a), 1.37−1.46 (m, 3H, CH2, H13b), 1.59−1.71 (m, 2H, CH2),
8001.96−2.09 (m, 3H, CH2, H11a), 2.14−2.27 (m, 3H, CH2, H11b), 3.53−
8013.61 (m, 1H, CHOH), 3.86 (s, 3H, CH3O), 4.34 (d, J = 5.7 Hz, 2H,
802CH2NH), 5.35−5.44 (m, 1H, CHCH), 5.47−5.56 (m, 1H, CHCH),
8035.72 (br s, 2H, CH2NH, OH), 6.79 (ddd, 3H, J = 16.1, 9.9, 5.0 Hz,
804HAr).
13C NMR (101 MHz, CDCl3) δ = 14.23 (CH3), 22.75 (CH2),
80525.79 (CH2), 25.86 (CH2), 29.06 (CH2), 29.26 (CH2), 29.35 (CH2),
80629.46 (CH2), 29.49 (CH2), 31.97 (CH2), 32.73 (CH2), 36.91 (CH2),
80736.96 (CH2), 40.82 (CHCH2CHO), 43.65 (CH2NH), 56.07
808(CH3O), 71.07 (CHOH), 110.86 (CAr), 114.53 (CAr), 120.91
809(CAr), 126.12 (CHCH), 130.54 (CAr), 134.68 (CHCH), 145.26
810(CAr), 146.84 (CAr), 173.01 (NHCO). HR-MS (ESI
+), m/z: [M +
811 gH]+ calcd for C26H44NO4 434.3265; found 434.3293.
812Methyl 12-Oxooctadec-(9E)-enoate (13). CrO3 (960 mg, 9.6
813mmol) and pyridine (1.5 mL, 19.2 mmol) were added to a solution of
814compound 10 (500 mg, 1.6 mmol) in DCM (6 mL). The mixture was
815vigorously stirred at room temperature for 2 h. The reaction mixture
816was ﬁltered over Celite and washed with 1 M HCl. The organic phase
817was dried over anhydrous Na2SO4, ﬁltered and the solvent was
818evaporated under reduced pressure to yield the ketone 136 (246 g,
81949%) as a yellowish oil after the puriﬁcation by silica gel column
820chromatography (petroleum ether/Et2O 98:2). Rf = 0.48 (petroleum
821ether/Et2O 9:1). IR (ATR) ν = 2925, 2854, 1738, 1715, 1435, 1362,
8221195, 1170, 968, 725 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.87 (t,
8233H, J = 6.5 Hz, CH3), 1.23−1.38 (m, 14H, CH2), 1.51−1.64 (m, 4H,
824CH2), 1.96−2.08 (m, 2H, CH2), 2.29 (t, J = 6.9 Hz, 2H, CH2), 2.41
825(t, 2H, J = 6.9 Hz, COCH2), 3.07 (d, 2H, J = 5.2 Hz, CH2CO), 3.66
826(s, 3H, CH3O), 5.45−5.56 (m, 2H, CHCH). 13C NMR (101 MHz,
827CDCl3) δ = 14.16 (CH3), 22.63 (CH2), 23.84 (CH2), 25.06 (CH2),
82829.03 (CH2), 29.06 (CH2), 29.21 (2 × CH2), 29.27 (CH2), 31.73
829(CH2), 32.67 (CH2), 34.22(CH2), 42.31 (COCH2), 46.95 (CH2CO),
83051.57 (CH3O), 122.13 (CHCH), 135.16 (CHCH), 174.42 (COO-),
831 g209.95 (COCH2).
83212-Oxooctadec-(9E)-enoic Acid (14). Novozym 435 (20 mg,
83350% w/w) was added to a solution of the methyl ester 13 (20 mg,
8340.06 mmol) in a mixture of H2O (31 μL) and tert-BuOH (138 μL).
835The reaction mixture was stirred at 45 °C for 24 h. The mixture was
836ﬁltered and the solvent was evaporated under reduced pressure to
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b00734
J. Med. Chem. XXXX, XXX, XXX−XXX
M
837 yield the acid 14 (17 mg, 89%) as a white solid. Mp = 71−73 °C. IR
838 (ATR) ν = 3121, 2954, 2918, 2848, 1701, 1263, 1082, 962, 720, 689
839 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.87 (t, 3H, J = 6.9 Hz, CH3),
840 1.26−1.36 (m, 14H, CH2), 1.50−1.58 (m, 2H, CH2), 1.58−1.66 (m,
841 2H, CH2), 1.98−2.08 (m, 2H, CH2), 2.34 (t, 2H, J = 6.9 Hz, CH2),
842 2.41 (t, 2H, J = 6.9 Hz, COCH2), 3.08 (d, 2H, J = 5.2 Hz, CH2CO),
843 5.44−5.57 (m, 2H, CHCH). 13C NMR (101 MHz, CDCl3) δ = 14.17
844 (CH3), 22.63 (CH2), 23.85 (CH2), 24.79 (CH2), 29.03 (2 × CH2),
845 29.12 (CH2), 29.18 (CH2), 29.26 (CH2), 31.73 (CH2), 32.66 (CH2),
846 34.09 (CH2), 42.32 (COCH2), 46.95 (CH2CO), 122.13 (CHCH),
847 135.17 (CHCH), 179.59 (COOH), 210.13 (COCH2). HR-MS
848 (ESI+), m/z: [M + Na]+ calcd for C18H32O3Na 319.2244; found
g 849 319.2267.
850 N-(4′-Hydroxy-3′-methoxybenzyl)-12-oxooctadec-(9E)-en-
851 amide (15). General procedure I was applied to a solution of the acid
852 14 (210 mg, 0.71 mmol) dissolved in anhydrous DMF (10 mL),
853 amine hydrochloride salt 3 (148 mg, 0.78 mmol), DIPEA (400 μL,
854 2.1 mmol), and HATU (404 mg, 1.06 mmol). The compound 15 was
855 obtained (52 mg, 17%) as an oﬀ-white solid after the puriﬁcation by
856 silica gel ﬂash column chromatography (petroleum ether/EtOAc 7:3).
857 Mp = 71−73 °C. Rf = 0.36 (petroleum ether/EtOAc 7:3). IR (ATR)
858 ν = 3393, 3312, 2917, 2850, 1703, 1636, 1554, 1509, 1242, 1125, 967,
859 705 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.87 (t, 3H, J = 6.9 Hz,
860 CH3), 1.22−1.38 (m, 14H, CH2), 1.50−1.58 (m, 2H, CH2), 1.59−
861 1.69 (m, 2H, CH2), 1.97−2.04 (m, 2H, CH2), 2.19 (t, 2H, J = 7.4 Hz,
862 CH2), 2.40 (t, 2H, J = 7.4 Hz, COCH2), 3.08 (d, 2H, J = 5.2 Hz,
863 CH2CO), 3.87 (s, 3H, CH3O), 4.35 (d, 2H, J = 5.7 Hz, CH2NH),
864 5.47−5.52 (m, 2H, CHCH), 5.67 (s, 1H, CH2NH), 5.73 (br s, 1H,
865 OH), 6.73−6.87 (6.79 (ddd, 3H, J = 12.5, 9.9, 5.0 Hz, HAr). 13C
866 NMR (101 MHz, CDCl3) δ = 14.17 (CH3), 22.63 (CH2), 23.86
867 (CH2), 25.86 (CH2), 29.03 (CH2), 29.05 (CH2), 29.23 (CH2), 29.26
868 (CH2), 29.36 (CH2), 31.73 (CH2), 32.64 (CH2), 36.96 (CH2), 42.37
869 (COCH2), 43.66 (CH2NH), 46.89 (CH2CO), 56.07 (CH3O), 110.83
870 (CAr), 114.50 (CAr), 120.92 (CAr), 122.12 (CHCH), 130.56 (CAr),
871 135.11 (CHCH), 145.25 (CAr), 146.82 (CAr), 172.99 (NHCO),
872 210.08 (COCH2). HR-MS (ESI
+), m/z: [M + H]+ calcd for
g 873 C26H42NO4 432.3108; found 432.3137.
874 N - ( 4 ′ -Hydroxy -3 ′ -methoxybenzy l ) -3 -mercap to -
875 propanamide (17). General procedure I was applied to a solution of
876 mercaptopropionic acid (1.2 mL, 12.68 mmol) dissolved in
877 anhydrous DMF (30 mL), amine hydrochloride salt 3 (2.65 g,
878 13.95 mmol), DIPEA (6.63 mL, 38.04 mmol), and HATU (7.23 g,
879 19.02 mmol). Compound 17 was obtained after silica gel column
880 chromatography (petroleum ether/EtOAc 5:5) as sticky oil (2.14 g,
881 74%). Rf = 0.60 (petroleum ether/EtOAc 4:6). IR (ATR) ν = 3425,
882 2922, 2853, 1515, 836 cm−1. 1H NMR (400 MHz, (CH3)2CO) δ =
883 1.86 (t, 1H, J = 8.2 Hz, SH), 2.54 (t, 2H, J = 6.7 Hz, CH2), 2.70−2.82
884 (m, 2H, CH2SH), 3.80 (s, 3H, CH3O), 4.31 (d, 2H, J = 5.9 Hz,
885 CH2NH), 6.74 (d, 2H, J = 1.0 Hz, HAr, OH), 6.92 (s, 1H, HAr), 7.48
886 (s, 2H, HAr, CH2NH).
13C NMR (101 MHz, (CH3)2CO) δ = 20.10
887 (CH2SH), 39.71 (CH2), 42.47 (CH2NH), 55.33 (CH3O), 111.25
888 (CAr), 114.66 (CAr), 120.16 (CAr), 130.83 (CAr), 145.61 (CAr), 147.36
889 (CAr), 170.16 (NHCO). HR-MS (ESI
+), m/z: [M + H]+ calcd for
g 890 C11H15NO3S, 242.0845; found 242.0861.
891 3-Selenocyanatopropanoic Acid (19). To a solution of 3-
892 bromopropionic acid 18 (1.5 g, 9.8 mmol) in water (3 mL) was
893 added Na2CO3 until pH 7. A volume of 14 mL of 10% KSeCN (1.41
894g, 9.8 mmol, 1 equiv) aqueous solution was added. The mixture
895stirred at room temperature for 2 days. After removing partially the
896solvent under reduced pressure, the crude was dissolved in Et2O and
897washed with 1 M HCl, water and brine. The organic solution was
898dried over Na2SO4, ﬁltered and the solvent was removed under
899reduced pressure to yield the 3-selenocyanatopropanoic acid 197as a
900yellow oil (1.39 g, 80%) which was used in the next step without
901further puriﬁcation. IR (ATR) ν = 3024, 2649, 2152, 1703, 1401
902cm−1. 1H NMR (400 MHz, CDCl3) δ = 3.07 (t, 2H, J = 6.4 Hz,
903CH2SeCN), 3.24 (dd, 2H, J = 6.4 Hz, CH2CH2SeCN), 9.52 (br s, 1H,
904COOH). 13C NMR (101 MHz, CDCl3) δ = 22.89 (CH2SeCN), 34.90
905(CH2CH2SeCN), 101.68 (SeCN), 176.86 (COOH).
906N-(4′-Hydroxy-3′-methoxybenzyl)-3-selenocyanato-
907propanamide (20). General procedure I was applied to a solution of
908compound 19 (1.3 g, 7.30 mmol), amine hydrochloride salt 3 (1.52 g,
9098.03 mmol), DIPEA (3.82 mL, 21.9 mmol), and HATU (4.16 g,
91010.95 mmol) in anhydrous DMF (20 mL). Compound 20 was
911aﬀorded after silica gel column chromatography (petroleum ether/
912EtOAc 5:5) as a white sticky solid (2.14 g, 60%). Rf = 0.65 (petroleum
913ether/EtOAc 4:6). IR (ATR) ν = 3315, 2924, 2853, 2148, 1638, 1235
914cm−1. 1H NMR (400 MHz, (CH3)2CO) δ = 2.94 (t, 2H, J = 6.4 Hz,
915COCH2), 3.34 (t, 2H, J = 6.4 Hz, CH2SeCN), 3.81 (s, 3H, CH3),
9164.30 (d, 2H, J = 5.8 Hz, CH2NH), 6.75 (s, 2H, HAr), 6.91 (s, 1H,
917HAr), 7.48 (s, 1H, OH), 7.72 (s, 1H, CH2NH).
13C NMR (101 MHz,
918(CH3)2CO) δ = 24.79 (CH2SeCN), 34.84 (CH2CH2SeCN), 42.73
919(CH2NH), 55.33 (CH3O), 104.64 (SeCN), 111.35 (CAr), 114.72
920(CAr), 120.32 (CAr), 130.19 (CAr), 145.79 (CAr), 147.38 (CAr), 170.92
921(NHCO). HR-MS (ESI+), m/z: [M + H]+ calcd for C12H15N2O3Se,
922 g315.0248; found 315.0242.
923N,N-Di-Boc-L-cystine (22). General procedure III was applied to
924L-cystine 21 (10 g, 41.67 mmol), Boc2O (27.25 g, 124.85 mmol), and
925Et3N (17.5 mL, 125.38 mmol) in water (150 mL) to yield compound
926228 as a white solid, which was thoroughly washed with petroleum
927ether several times (17.56 g, 96%). Mp: 145−146 °C. IR (ATR) ν =
9283366, 2985, 2936, 1682, 1511, 1163, 1052, 868 cm−1. 1H NMR (400
929MHz, (CD3)2SO) δ = 1.37 (s, 18H, Boc), 2.87 (dd, 2H, J = 13.5, 10.1
930Hz, CHCH2), 3.09 (dd, 2H, J = 13.5, 4.4 Hz, CHCH2), 4.16 (td, 2H,
931J = 10.1, 4.4 Hz, CHCH2), 7.18 (d, 2H, J = 8.4 Hz, NH), 12.79 (s,
9322H, COOH). 13C NMR (101 MHz, (CD3)2SO) δ = 28.60
933(C(CH3)3), 52.96 (CHCH2), 78.70 (C(CH3)3), 155.79 (NHCO2),
934 g172.82 (COOH).
935Di-[(2R)-N-Boc-amino-1-((4′-hydroxy-3′-methoxybenzyl)-
936amino)-1-oxoprop-3-yl]disulfane (23). To a solution of com-
937pound 22 (5 g, 11.35 mmol) in anhydrous DMF (50 mL) were added
938HOBt (4.6 g, 34.05 mmol), Et3N (4.74 mL, 34.05 mmol), and the
939amine hydrochloride salt 3 (5.16 g, 27.24 mmol). The mixture was
940stirred at 0 °C during 30 min. EDCI (6.52 g, 34 mmol) was added
941and the mixture stirred at room temperature during 20 h. To the
942mixture were added EtOAc and brine, and the aqueous phase was
943extracted with EtOAc. The combined organic solutions were washed
944with 1 M HCl, saturated NaHCO3, and brine. The organic solution
945was dried over anhydrous Na2SO4, ﬁltered and the solvent was
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946 evaporated under reduced pressure. Compound 23 was aﬀorded after
947 silica gel column chromatography (PE/EtOAc 1:9) as a white solid
948 (7.58 g, 94%). Rf = 0.24 (petroleum ether/EtOAc 1:9). Mp: 167−170
949 °C. [α]D20 −67.42 (c 0.75, MeOH). IR (ATR) ν = 3330, 2975, 2935,
950 1658, 1511, 1272, 1033 cm−1. 1H NMR (400 MHz, (CD3)2SO) δ =
951 1.36 (s, 18H, C(CH3)3), 2.86 (dd, 2H, J = 13.0, 9.9 Hz, CHCH2),
952 3.07 (dd, 2H, J = 13.0, 4.8 Hz, CHCH2), 3.72 (s, 6H, CH3O), 4.02−
953 4.32 (m, 6H, CHCH2, CH2NH), 6.55−6.72 (m, 4H, HAr, NHBoc),
954 6.79 (s, 2H, HAr), 7.06 (d, 2H, J = 8.4 Hz, HAr), 8.31 (t, 2H, J = 5.4
955 Hz, CH2NH), 8.78 (br s, 2H, OH).
13C NMR (101 MHz, (CD3)2SO)
956 δ = 28.59 (C(CH3)3), 40.59 (CHCH2), 42.40 (CH2NH), 54.17
957 (CHCH2), 55.92 (CH3O), 78.73 (C(CH3)3), 111.82 (CAr), 115.53
958 (CAr), 119.88 (CAr), 130.37 (CAr), 145.76 (CAr), 147.85 (CAr), 155.70
959 (NHCO2), 170.60 (NHCO). HR-MS (ESI
+), m/z: [M + H]+ calcd
g 960 for C32H47N4O10S2, 711.2734; found 711.2793.
961 N-(4′-Hydroxy-3′-methoxy)benzyl-(2R)-(Boc-amino)-3-
962 mercaptopropanamide (24). General procedure IV (SS bond
963 cleavage) was applied to compound 23 (7 g, 9.86 mmol) dissolved in
964 THF (60 mL), P(nBu)3 (2.55 mL, 10.35 mmol) in the presence of
965 water (1.3 mL). Compound 24 was aﬀorded after silica gel column
966 chromatography (petroleum ether/EtOAc 5:5) as a white solid (5.11
967 g, 73%). Rf = 0.42 (petroleum ether/EtOAc 4:6). Mp: 108−110 °C.
968 [α]D
20 −15.65 (c 1.6, MeOH). IR (ATR) ν = 3456, 3327, 2989, 2934,
969 2847, 1678, 1513, 1240 cm−1. 1H NMR (400 MHz, CDCl3) δ = 1.41
970 (s, 9H, C(CH3)3), 1.54 (t, 1H, J = 10.7 Hz, SH), 2.74 (ddd, 1H, J =
971 13.8, 10.2, 6.1 Hz, CHCH2), 3.09 (ddd, 1H, J = 13.6, 7.6, 4.6 Hz,
972 CHCH2), 3.84 (s, 3H, CH3O), 4.25−4.44 (m, 3H, CHCH2,
973 CH2NH), 5.48 (d, 1H, J = 7.8 Hz, CH2NH), 5.81 (br s, 1H, OH),
974 6.67−6.89 (m, 4H, HAr, NHBoc). 13C NMR (101 MHz, CDCl3) δ =
975 26.96 (CHCH2), 28.23 (C(CH3)3), 43.47 (CH2NH), 55.67
976 (CHCH2), 55.93 (CH3O), 80.69 (C(CH3)3), 110.47 (CAr), 114.44
977 (CAr), 120.58 (CAr), 129.66 (CAr), 145.12 (CAr), 146.74 (CAr), 155.46
978 (NHCO2), 169.88 (NHCO). HR-MS (ESI
+), m/z: [M + H]+ calcd
g 979 for C16H24N2O5SNa, 379.1298; found 379.1326.
980 N,N-Di-Boc-L-selenocystine (26). General procedure III was
981 applied to L-selenocystine 25 (1.5 g, 4.49 mmol), Boc2O (3.24 g,
982 13.48 mmol), and Et3N (1.88 mL, 13.48 mmol) in water (22 mL) to
983 yield compound 269 as a yellow solid (1.55 g, 65%), which was used
984 in the next step without further puriﬁcation. Mp: 145−147 °C. [α]D20
985 −75.63 (c 1.5, DCM). IR (ATR) ν = 3364, 2979, 2557, 1698, 1662,
986 1506 cm−1. 1H NMR (400 MHz, (CD3)2SO) δ = 1.37 (s, 18H,
987 C(CH3)3), 3.10 (dd, 2H, J = 11.9, 10.2 Hz, CHCH2), 3.28 (dd, 2H, J
988 = 11.9, 4.7 Hz, CHCH2), 4.06−4.21 (m, 2H, CHCH2), 7.17 (d, 2H, J
989 = 8.3 Hz, NH), 12.79 (s, 2H, COOH). 13C NMR (101 MHz,
990 (CD3)2SO) δ = 28.61 (C(CH3)3), 31.38 (CHCH2), 54.68 (CHCH2),
g 991 78.71 (C(CH3)3), 155.71 (NHCO2), 172.91 (COOH).
992 Di-[(2R)-N-Boc-amino-1-((4′-hydroxy-3′-methoxybenzyl)-
993 amino)-1-oxoprop-3-yl]diseleno (27). To a solution of compound
994 26 (1.5 g, 2.80 mmol) in anhydrous DMF (14 mL) were added HOBt
995 (1.14 g, 8.4 mmol), Et3N (1.18 mL, 8.4 mmol), and the amine
996hydrochloride salt 3 (1.27 g, 6.72 mmol). The mixture was stirred at 0
997°C during 30 min. EDCI (1.61 g, 8.4 mmol) was added and the
998mixture stirred at room temperature during 20 h. To the mixture were
999added EtOAc and brine, and the aqueous phase was extracted. The
1000combined organic layers were washed with 1 M HCl, saturated
1001NaHCO3, and brine. The organic phase was dried over anhydrous
1002Na2SO4, ﬁltered, and the solvent was evaporated under reduced
1003pressure. Compound 27 was aﬀorded after silica gel column
1004chromatography (petroleum ether/EtOAc 1:9) as a white solid
1005(1.98 g, 88%). Rf = 0.26 (petroleum ether/EtOAc 5:5). Mp: 93−95
1006°C. [α]D
20 42.94 (c 0.7, DCM). IR (ATR) ν = 3314, 2975, 2932, 1654,
10071513, 1157 cm−1. 1H NMR (400 MHz, CDCl3) δ = 1.26 (s, 18H,
1008C(CH3)3), 3.12−3.30 (m, 4H, CHCH2), 3.83 (s, 6H, CH3O), 4.25
1009(dd, 2H, J = 14.7, 5.4 Hz, CH2NH), 4.48 (dd, 2H, J = 14.7, 6.5 Hz,
1010CH2NH), 4.75−4.94 (m, 2H, CHCH2), 5.58 (d, 2H, J = 9.7 Hz,
1011NHBoc), 5.63 (s, 2H, OH), 6.77 (ddd, 6H, J = 12.5, 9.9, 5.0, HAr),
10128.06 (t, 2H, J = 5.6 Hz, CH2NH).
13C NMR (101 MHz, CDCl3) δ =
101328.15 (C(CH3)3), 37.43 (CHCH2), 43.28 (CH2NH), 55.24
1014(CHCH2), 55.86 (CH3O), 78.98 (C(CH3)3), 110.44 (CAr), 114.24
1015(CAr), 120.77 (CAr), 130.03 (CAr), 145.00 (CAr), 146.58 (CAr), 155.65
1016(NHCO2), 170.53 (NHCO). HR-MS (ESI
+), m/z: [M + H]+ calcd
1017 gfor C32H46N4O10Se2, 807.1623; found 807.1621.
10181-Hexadecanol (29a). General procedure V was applied to
1019methyl palmitate 28a (1 g, 3.69 mmol), LiAlH4 (280 mg, 7.38 mmol)
1020in anhydrous THF (20 mL). Compound 29a10 was aﬀorded after
1021silica gel column chromatography (petroleum ether/Et2O 9:1) as a
1022white solid (875 mg, 98%). Rf = 0.88 (petroleum ether/Et2O 9:1).
1023Mp: 50−52 °C. IR (ATR) ν = 3320, 3226, 2915, 2919, 2847, 1462
1024cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.87 (t, 3H, J = 6.9 Hz, CH3),
10251.15−1.41 (m, 24H, CH2), 1.45−1.64 (m, 4H, CH2, HOCH2CH2),
10263.62 (t, 2H, J = 6.9 Hz, HOCH2CH2).
13C NMR (101 MHz, CDCl3)
1027δ = 14.08 (CH3), 22.67 (CH2), 25.74 (CH2), 29.35 (CH2), 29.43
1028(CH2), 29.60 (CH2), 29.61 (CH2), 29.65 (2 × CH2), 29.67 (CH2),
102929.68 (3 × CH2), 31.91 (CH2), 32.78 (HOCH2CH2), 62.99
1030(HOCH2CH2).
1031(9Z)-Octadecen-1-ol (29b). General procedure V was applied to
1032methyl oleate 28b (2.5 g, 8.43 mmol), LiAlH4 (640 mg, 16.86 mmol)
1033in anhydrous THF (50 mL). Compound 29b11 was aﬀorded after
1034silica gel column chromatography (petroleum ether/Et2O 9:1) as a
1035brown oil (2.19 g, 97%). Rf = 0.88 (petroleum ether/Et2O 9:1). IR
1036(ATR) ν = 3320, 2921, 2852, 1463, 1055 cm−1. 1H NMR (400 MHz,
1037CDCl3) δ = 0.87 (t, 3H, J = 6.9 Hz, CH3), 1.16−1.41 (m, 22H, CH2),
10381.47−1.62 (m, 2H, HOCH2CH2), 1.73 (s, 1H, OH), 2.00 (q, 4H, J =
10396.4 Hz, CH2CH, CHCH2), 3.61 (t, 2H, J = 6.9 Hz, HOCH2CH2),
10405.25−5.47 (m, 2H, CHCH). 13C NMR (101 MHz, CDCl3) δ =
104114.07 (CH3), 22.65 (CH2), 25.73 (CH2), 27.16 (CH2CH), 27.18
1042(CHCH2), 29.22 (CH2), 29.30 (2 × CH2), 29.40 (CH2), 29.49
1043(CH2), 29.50 (CH2), 29.72 (CH2), 29.74 (CH2), 31.88 (CH2), 32.75
1044(HOCH2CH2), 62.93 (HOCH2CH2), 129.76 (CHCH), 129.90
1045(CHCH).
1046(9Z,12Z)-Octadecadien-1-ol (29c). General procedure V was
1047applied to methyl linoleate 28b (1 g, 3.39 mmol), LiAlH4 (257 mg,
10486.79 mmol) in anhydrous THF (30 mL). Compound 29c12 was
1049aﬀorded after silica gel column chromatography (petroleum ether/
1050Et2O 9:1) as a colorless oil (885 mg, 98%). Rf = 0.88 (petroleum
1051ether/Et2O 9:1). IR (ATR) ν = 3373, 2926, 2855, 1719, 1463 cm
−1.
1052
1H NMR (400 MHz, CDCl3) δ = 0.89 (t, 3H, J = 6.9 Hz, CH3),
10531.19−1.48 (m, 16H, CH2), 1.51−1.61 (m, 2H, HOCH2CH2), 2.05
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1054 (q, 4H, J = 6.4 Hz, CH2CH, CHCH2), 2.77 (t, 2H, J = 6.9 Hz,
1055 CHCH2CH), 3.59−3.67 (m, 2H, HOCH2CH2), 5.14−5.52 (m, 4H, 2
1056 × CHCH). 13C NMR (101 MHz, CDCl3) δ = 14.04 (CH3), 22.55
1057 (CH2), 25.61 (CHCH2CH), 25.71 (CH2), 27.18 (CH2CH), 27.20
1058 (CHCH2), 29.22 (CH2), 29.33 (CH2), 29.38 (CH2), 29.48 (CH2),
1059 29.63 (CH2), 31.51 (CH2), 32.78 (HOCH2CH2), 63.03
1060 (HOCH2CH2), 127.89 (CHCH), 127.97 (CHCH), 130.08
1061 (CHCH), 130.08 (CHCH).
1062 1-Iodohexadecane (30a). General procedure VI was applied to
1063 compound 29a (1 g, 4.12 mmol), iodine (1.25 g, 4.95 mmol), PPh3
1064 (1.3 g, 4.95 mmol), and imidazole (0.85 g, 12.36 mmol) in toluene
1065 (15 mL). Compound 30a13 was aﬀorded after silica gel column
1066 chromatography (petroleum ether) as a yellow oil (1.08 g, 75%). Rf =
1067 0.1 (petroleum ether). IR (ATR) ν = 2920, 2851, 1464, 1376, 1171,
1068 719 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.88 (t, 3H, J = 6.9 Hz,
1069 CH3), 1.26 (s, 24H, CH2), 1.34−1.41 (m, 2H, ICH2CH2CH2), 1.75−
1070 1.87 (m, 2H, ICH2CH2), 3.18 (t, 2H, J = 6.9 Hz, ICH2).
13C NMR
1071 (101 MHz, CDCl3) δ = 7.21 (ICH2), 14.11 (CH3), 22.69 (CH2),
1072 28.55 (CH2), 29.36 (CH2), 29.42 (CH2), 29.55 (CH2), 29.61 (CH2),
1073 29.65 (2 × CH2), 29.68 (2 × CH2), 29.69 (CH2), 30.51 (CH2), 31.92
1074 (CH2), 33.58 (ICH2CH2).
1075 1-Iodo-(9Z)-octadecene (30b). General procedure VI was
1076 applied to compound 29b (2 g, 7.45 mmol), iodine (2.27 g, 8.94
1077 mmol), PPh3 (2.34 g, 8.94 mmol), and imidazole (1.52 g, 22.35
1078 mmol) in toluene (30 mL). Compound 30b14 was aﬀorded after silica
1079 gel column chromatography (petroleum ether/Et2O 9:1) as a yellow
1080 oil (2.42 g, 86%). Rf = 0.1 (petroleum ether/Et2O 9:1). IR (ATR) ν =
1081 2921, 2852, 1462, 1181 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.88
1082 (t, 3H, J = 6.9 Hz, CH3), 1.16−1.48 (m, 22H, CH2), 1.72−1.91 (m,
1083 2H, ICH2CH2), 2.01 (q, 4H, J = 6.4 Hz, CH2CH, CHCH2), 3.18 (t,
1084 2H, J = 6.9 Hz, ICH2), 5.21−5.48 (m, 2H, CHCH). 13C NMR
1085 (101 MHz, CDCl3) δ = 7.24 (ICH2), 14.10 (CH3), 22.67 (CH2),
1086 27.15 (CH2CH), 27.21 (CHCH2), 28.50 (CH2), 29.16 (CH2), 29.29
1087 (CH2), 29.31 (CH2), 29.51 (CH2), 29.68 (CH2), 29.75 (CH2), 30.48
1088 (CH2), 31.89 (CH2), 33.55 (ICH2CH2), 129.73 (CHCH), 129.98
1089 (CHCH).
1090 18-Iodo-(6Z,9Z)-octadecadiene (30c). General procedure VI
1091 was applied to compound 29c (850 mg, 3.18 mmol), iodine (968 mg,
1092 3.81 mmol), PPh3 (1 g, 3.81 mmol), and imidazole (650 mg, 9.54
1093 mmol) in toluene (15 mL). Compound 30c14 was aﬀorded after silica
1094 gel column chromatography (petroleum ether) as a yellow oil (1.13 g,
1095 95%). Rf = 0.1 (petroleum ether/Et2O 9:1). IR (ATR) ν = 3439,
1096 2926, 2855, 1707, 1458, 1175 cm−1. 1H NMR (400 MHz, CDCl3) δ =
1097 0.89 (t, 3H, J = 6.9 Hz, CH3), 1.18−1.50 (m, 16H, CH2), 1.78−1.86
1098 (m, 2H, ICH2CH2), 2.05 (q, 4H, J = 6.4 Hz, CH2CH, CHCH2), 2.77
1099 (t, 2H, J = 6.9 Hz, CHCH2CH), 3.18 (t, 2H, J = 6.9 Hz, ICH2CH2),
1100 5.25−5.50 (m, 2 × CHCH). 13C NMR (101 MHz, CDCl3) δ =
1101 7.20 (ICH2), 14.07 (CH3), 22.57 (CH2), 25.63 (CHCH2CH), 27.18
1102 (CH2CH), 27.20 (CHCH2), 28.50 (CH2), 29.17 (CH2), 29.30 (CH2),
1103 29.34 (CH2), 29.59 (CH2), 30.48 (CH2), 31.52 (CH2), 33.55
1104 (ICH2CH2), 127.89 (CHCH), 128.02 (CHCH), 130.02 (CH
g 1105 CH), 130.18 (CHCH).
1106 Hexadecyl 2-Iodoacetate (32). To a solution of iodoacetic acid
1107 31 (500 mg, 2.69 mmol) in toluene (5 mL) were added 1-
1108 hexadecanol (978 mg, 4.03 mmol, 1.5 equiv) and Novozym 435 (150
1109 mg). The reaction mixture was stirred at 50 °C for 2 days. The
1110 mixture was ﬁltered oﬀ, EtOAc was added, and the organic phase was
1111 washed with saturated solution of NaHCO3, water, and brine. The
1112 organic solution was then dried over Na2SO4, and the solvent was
1113 removed under reduced pressure. Compound 3215 was aﬀorded after
1114 silica gel column chromatography (petroleum ether/Et2O 9:1) as a
1115 yellow oil (562 mg, 51%). Rf = 0.36 (petroleum ether/Et2O 9:1). IR
1116 (ATR) ν = 2920, 2851, 1733, 1259, 1089 cm−1. 1H NMR (400 MHz,
1117 CDCl3) δ = 0.86 (t, 3H, J = 6.9 Hz, CH3), 1.14−1.41 (m, 26H, CH2),
11181.54−1.74 (m, 2H, COOCH2CH2), 3.68 (s, 2H, ICH2), 4.13 (t, 2H, J
1119= 6.9 Hz, COOCH2CH2).
13C NMR (101 MHz, CDCl3) δ = 5.19
1120(ICH2), 14.27 (CH3), 22.84 (CH2), 25.90 (CH2), 28.50 (CH2), 29.33
1121(CH2), 29.51 (CH2), 29.63 (CH2), 29.70 (CH2), 29.78 (CH2), 29.80
1122(CH2), 29.82 (CH2), 29.84 (3 × CH2), 32.07 (CH2), 66.41
1123 g(COOCH2), 169.00 (COOCH2).
1124Methyl (12R)-[(tert-Butyldimethylsilyl)oxy]octadec-(9Z)-
1125enoate (33). To a solution of methyl ricinoleate 4 (2 g, 6.4
1126mmol) in DCM (40 mL) were added DMAP (31 mg, 0.25 mmol)
1127and Et3N (2.23 mL, 16 mmol). TBDMS-Cl was slowly added (1.5 g,
11289.92 mmol). The mixture was stirred at room temperature for 2 days.
1129Then, the organic phase was washed with 1 M HCl, water, and brine,
1130dried over anhydrous NaSO4 and the solvent was removed under
1131reduced pressure. Compound 3316 was aﬀorded after silica gel column
1132chromatography (petroleum ether/Et2O 9:1) as a colorless oil (2.37
1133g, 87%). Rf = 0.1 (petroleum ether/Et2O 9:1). [α]D
20 9.98 (c 2.8,
1134DCM). IR (ATR) ν = 2927, 2855, 1742, 1461, 1251 cm−1. 1H NMR
1135(400 MHz, CDCl3) δ = 0.04 (s, 6H, Si(CH3)2), 0.78−0.95 (m, 12H,
1136SiC(CH3)3, CH3), 1.16−1.46 (m, 18H, CH2), 1.51−1.68 (m, 2H,
1137COCH2CH2), 2.01 (q, 2H, J = 6.4 Hz, CH2CH), 2.17 (t, 2H, J = 6.9
1138Hz, CHCH2), 2.29 (t, 2H, J = 6.9 Hz, COCH2CH2), 3.59−3.73 (m,
11394H, CH3O, CH2CHO), 5.29−5.51 (m, 2H, CHCH). 13C NMR
1140(101 MHz, CDCl3) δ = −4.59 (SiCH3), −4.38 (SiCH3), 14.06 (CH3),
114118.11 (SiC(CH3)3), 22.61 (CH2), 24.92 (COCH2CH2), 25.38 (CH2),
114225.89 (SiC(CH3)3), 27.40 (CH2CH), 29.10 (CH2), 29.12 (CH2),
114329.14 (CH2), 29.45 (CH2), 29.58 (CH2), 31.87 (CH2), 34.06
1144(COCH2CH2), 35.23 (CHCH2), 36.84 (CH2), 51.38 (CH3O), 72.37
1145(CH2CHO), 125.95 (CHCH), 131.28 (CHCH), 174.23
1146(COOH).
1147(12R)-[(tert-Butyldimethylsilyl)oxy]octadec-(9Z)-en-1-ol
1148(34). General procedure V was applied to compound 33 (2.20 g, 5.15
1149mmol) with anhydrous LiAlH4 (390 mg, 10.30 mmol) in dry THF
1150(50 mL). Compound 3417 was aﬀorded after silica gel column
1151chromatography (petroleum ether/Et2O 9:1) as a brown oil (1.91 g,
115293%). Rf = 0.86 (petroleum ether/Et2O 9:1). [α]D
20 13.21 (c 2.6,
1153DCM). IR (ATR) ν = 3330, 2926, 2854, 1461, 1253, 1054 cm−1. 1H
1154NMR (400 MHz, CDCl3) δ = 0.04 (s, 6H, Si(CH3)2), 0.78−0.93 (m,
115512H, SiC(CH3)3, CH3), 1.14−1.50 (m, 20H, CH2), 1.51−1.62 (m,
11562H, HOCH2CH2), 2.04 (q, 2H, J = 6.4 Hz, CH2CH), 2.18 (t, 2H, J =
11576.9 Hz, CHCH2), 3.54−3.74 (m, 3H, HOCH2CH2, CH2CHO),
11585.30−5.50 (m, 2H, CHCH). 13C NMR (101 MHz, CDCl3) δ =
1159−4.58 (SiCH3), −4.37 (SiCH3), 14.07 (CH3), 18.12 (SiC(CH3)3),
116022.61 (CH2), 25.39 (CH2), 25.72 (CH2), 25.90 (SiC(CH3)3), 27.43
1161(CH2CH), 29.26 (CH2), 29.38 (CH2), 29.46 (CH2), 29.49 (CH2),
116229.64 (CH2), 31.87 (CH2), 32.77 (HOCH2CH2) 35.24 (CHCH2),
116336.84 (CH2), 63.00 (HOCH2CH2), 72.40 (CH2CHO), 125.91
1164 g(CHCH), 131.36 (CHCH).
1165(12R)-[(tert-Butyldimethylsilyl)oxy]-1-iodooctadec-(9Z)-ene
1166(35). General procedure VI was applied to compound 34 (1.8 g, 4.51
1167mmol), iodine (1.37 g, 5.42 mmol), PPh3 (1.42 g, 5.42 mmol), and
1168imidazole (921 mg, 13.53 mmol) in toluene (20 mL). Compound 35
1169was aﬀorded after silica gel column chromatography (petroleum
1170ether) as a colorless oil (1.86 g, 81%). Rf = 0.1 (petroleum ether/Et2O
11719:1). [α]D
20 7.12 (c 0.6, DCM). IR (ATR) ν = 2925, 2854, 1461, 1252,
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1172 1063 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.05 (s, 6H, Si(CH3)2),
1173 0.80−0.97 (m, 12H, SiC(CH3)3, CH3), 1.15−1.49 (m, 20H, CH2),
1174 1.71−1.92 (m, 2H, ICH2CH2), 2.02 (q, 2H, J = 6.4 Hz, CH2CH),
1175 2.18 (t, 2H, J = 6.9 Hz, CHCH2), 3.18 (t, 2H, J = 7.1 Hz, ICH2CH2),
1176 3.57−3.75 (m, 1H, CH2CHO), 5.29−5.52 (m, 2H, CHCH). 13C
1177 NMR (101 MHz, CDCl3) δ = −4.56 (SiCH3), −4.35 (SiCH3), 7.19
1178 (ICH2), 14.09 (CH3), 18.13 (SiC(CH3)3), 22.63 (CH2), 25.40 (CH2),
1179 25.91 (SiC(CH3)3), 27.42 (CH2CH), 28.50 (CH2), 29.21 (CH2),
1180 29.31 (CH2), 29.47 (CH2), 29.61 (CH2), 30.48 (CH2), 31.89 (CH2),
1181 33.55 (ICH2CH2), 35.25 (CHCH2), 36.86 (CH2), 72.38 (CH2CHO),
g 1182 125.97 (CHCH), 131.30 (CHCH).
1183 Octadec-(9Z)-ene-1-(12R)-diol (36). General procedure V was
1184 applied to methyl ricinoleate 4 (2.50 g, 8 mmol) with LiAlH4 (607
1185 mg, 16 mmol) in anhydrous THF (40 mL). Compound 3618 was
1186 aﬀorded after silica gel column chromatography (petroleum ether/
1187 Et2O 9:1) as a colorless oil (1.95 g, 86%). Rf = 0.82 (petroleum ether/
1188 Et2O 9:1). IR (ATR) ν = 3329, 2923, 2853, 1458, 1053 cm
−1. 1H
1189 NMR (400 MHz, CDCl3) δ = 0.87 (t, 3H, J = 6.9 Hz, CH3), 1.19−
1190 1.39 (m, 18H, CH2), 1.40−1.49 (m, 2H, CH2), 1.51−1.58 (m, 2H,
1191 HOCH2CH2), 1.59 (br s, 2H, OH), 2.04 (q, 2H, J = 6.4 Hz,
1192 CH2CH), 2.20 (t, 2H, J = 6.9 Hz, CHCH2), 3.62 (m, 3H,
1193 HOCH2CH2, CH2CHO), 5.29−5.47 (m, 1H, CHCH), 5.47−
1194 5.66 (m, 1H, CHCH). 13C NMR (101 MHz, CDCl3) δ = 14.06
1195 (CH3), 22.59 (CH2), 25.68 (CH2), 25.69 (CH2), 27.36 (CH2CH),
1196 29.17 (CH2), 29.31 (CH2), 29.33 (CH2), 29.40 (CH2), 29.59 (CH2),
1197 31.81 (CH2), 32.73 (HOCH2CH2), 35.32 (CHCH2), 36.81 (CH2),
1198 62.96 (HOCH2CH2), 71.49 (CH2CHO), 125.14 (CHCH), 133.39
1199 (CHCH).
1200 (12′R)-Hydroxyoctadec-(9′Z)-en-1-yl-4-methylbenzene-
1201 sulfonate (37). To a solution of compound 36 (1.6 g, 5.62 mmol) in
1202 a mixture of DCM and pyridine (6 mL, 5:5) were added TsCl (1.07 g,
1203 5.62 mmol, 1 equiv) in portions and DMAP (27 mg, 0.22 mmol). The
1204 mixture was stirred at room temperature for 20 h. The mixture was
1205 washed with 1 M HCl and extracted with EtOAc. The organic phase
1206 was dried over Na2SO4, and the solvent was removed under reduced
1207 pressure. Compound 3719 was aﬀorded after silica gel column
1208 chromatography (petroleum ether/Et2O 7:3) as a yellow oil (1.11 g,
1209 45%). Rf = 0.84 (petroleum ether/Et2O 7:3). [α]D
20 4.40 (c 1.4,
1210 DCM). IR (ATR) ν = 2924, 2854, 1458, 1358 cm−1. 1H NMR (400
1211 MHz, CDCl3) δ = 0.88 (t, 3H, J = 6.9 Hz, CH3), 1.11−1.39 (m, 18H,
1212 CH2), 1.39−1.54 (m, 2H, CH2), 1.53−1.70 (m, 2H, OCH2CH2) 2.03
1213 (q, 2H, J = 6.4 Hz, CH2CH), 2.20 (t, 2H, J = 6.9 Hz, CHCH2), 2.44
1214 (s, 3H, CH3C), 3.54−3.71 (m, 1H, CH2CHO), 4.01 (t, 2H, J = 6.9
1215 Hz, OCH2CH2), 5.31−5.47 (m, 1H, CHCH), 5.48−5.68 (m, 1H,
1216 CHCH), 7.33 (d, 2H, J = 8.5 Hz, HAr), 7.78 (d, 2H, J = 7.9 Hz,
1217 HAr).
13C NMR (101 MHz, CDCl3) δ = 14.06 (CH3), 21.60 (CH3C),
1218 22.59 (CH2), 25.28 (CH2), 25.69 (CH2), 27.35 (CH2CH), 28.78
1219 (OCH2CH2), 28.84 (CH2), 29.10 (CH2), 29.22 (CH2), 29.32 (CH2),
1220 29.56 (CH2), 31.81 (CH2), 35.34 (CHCH2), 36.83 (C-CH2), 70.64
1221 (OCH2CH2), 71.45 (CH2CHO), 125.23 (CHCH), 127.84 (2 ×
1222 CAr), 129.76 (2 × CAr), 133.22 (CAr), 133.27 (CHCH), 144.58
g 1223 (CAr).
12241″-Hexyl-12″-(Tosyloxy)dodec-(3″Z)-en-(1″R)-yl-2-phenyla-
1225cetate (38). To a solution of compound 37 (900 mg, 2.05 mmol) in
1226anhydrous toluene (10 mL), phenylacetic acid (307 mg, 2.25 mmol,
12271.1 equiv), DCC (1.02 g, 5.13 mmol, 2.5 equiv), and DMAP (500 mg,
12284.1 mmol, 2 equiv) were added. The mixture was left stirred at room
1229temperature overnight and then ﬁltered oﬀ to remove DCU. The
1230solvent was partially evaporated; the crude was dissolved in EtOAc
1231and washed with 1 M HCl, water, and brine. The organic phase was
1232dried over Na2SO4 and the solvent was removed under reduced
1233pressure. Compound 38 was aﬀorded after silica gel column
1234chromatography (petroleum ether/EtOAc 8:2) as a colorless oil
1235(935 mg, 82%). Rf = 0.53 (petroleum ether/EtOAc 8:2). [α]D
20 16.91
1236(c 5, DCM). IR (ATR) ν = 2925, 2855, 1730, 1361, 1187 cm−1. 1H
1237NMR (400 MHz, CDCl3) δ = 0.87 (t, 3H, J = 6.9 Hz, CH3), 1.11−
12381.39 (m, 18H, CH2), 1.42−1.56 (m, 2H, CH2), 1.58−1.67 (m, 2H,
1239OCH2CH2), 1.97 (q, 2H, J = 6.4, CH2CH), 2.13−2.38 (m, 2H,
1240CHCH2), 2.44 (s, 3H, CH3C) 3.58 (s, 2H, COCH2), 4.01 (t, 2H, J =
12416.9 Hz, OCH2CH2), 4.87 (p, 1H, J = 6.1 Hz, CH2CHO), 5.19−5.37
1242(m, 1H, CHCH), 5.37−5.55 (m, 1H, CHCH), 7.19−7.43 (m,
12437H, HAr), 7.79 (d, 2H, J = 8.0 Hz, HAr).
13C NMR (101 MHz,
1244CDCl3) δ = 14.04 (CH3), 21.61 (CH3C), 22.50 (CH2), 25.17 (CH2),
124525.31 (CH2), 27.27 (CH2CH), 28.80 (OCH2CH2), 28.88 (CH2),
124629.04 (CH2), 29.13 (CH2), 29.27 (CH2), 29.49 (CH2), 31.66 (CH2),
124731.89 (CHCH2), 33.53 (CH2), 41.74 (COCH2), 70.64 (OCH2CH2),
124874.44 (CH2CHO), 124.15 (CHCH), 126.92 (CAr), 127.85 (2 ×
1249CAr), 128.44 (2 × CAr), 129.20 (2 × CAr), 129.76 (2 × CAr), 132.57
1250(CHCH), 133.25 (CAr), 134.31 (CAr), 144.57 (CAr), 171.27
1251(OCOCH2). HR-MS (ESI
+), m/z: [M+NH4]
+ calcd for C33H52NO5S,
1252 g574.3561; found 573.3563.
12533-(Hexadecylthio)-N-(4′-hydroxy-3′-methoxybenzyl)-
1254propanamide (39). General procedure VII was applied to 32 (150
1255mg, 0.62 mmol), compound 30a (245 mg, 0.70 mmol), and Et3N
1256(175 μL, 1.24 mmol) dissolved in anhydrous DMF (4 mL).
1257Compound 39 was aﬀorded after silica gel column chromatography
1258(petroleum ether/EtOAc 7:3) as a white solid (136 mg, 42%). Mp =
125972−73 °C. Rf = 0.48 (petroleum ether/EtOAc 5:5). IR (ATR) ν =
12602925, 2855, 1730, 1361, 1187 cm−1. 1H NMR (400 MHz, CDCl3) δ =
12610.88 (t, 3H, J = 6.9 Hz, CH3), 1.23−1.32 (m, 24H, CH2), 1.56−1.60
1262(m, 4H, SCH2CH2), 2.40−2.58 (m, 4H, COCH2S, SCH2CH2), 2.84
1263(t, 2H, J = 6.9 Hz, CH2S), 3.88 (s, 3H, CH3O), 4.37 (d, 2H, J = 5.7
1264Hz, CH2NH), 5.59 (s, 1H, CH2NH), 5.90 (br s, 1H, OH), 6.81 (ddd,
12653H, J = 12.5, 9.9, 5.0 Hz, HAr).
13C NMR (101 MHz, CDCl3) δ =
126614.28 (CH3), 22.85 (CH2), 28.04 (CH2S), 29.05 (CH2), 29.40 (CH2),
126729.52 (CH2), 29.69 (CH2), 29.77 (CH2), 29.81 (3 × CH2), 29.85 (4
1268× CH2), 32.08 (CH2), 32.63 (COCH2), 37.07 (SCH2CH2), 43.80
1269(CH2NH), 56.13 (CH3O), 110.80 (CAr), 114.49 (CAr), 120.97 (CAr),
1270130.24 (CAr), 145.28 (CAr), 146.84 (CAr), 171.12 (NHCO). HR-MS
1271(ESI+), m/z: [M + H]+ calcd for C27H48NO3S, 466.3355; found
1272 g466.3378.
1273N-(4′-Hydroxy-3′-methoxybenzyl)-3-(octadec-(9″Z)-en-1-
1274ylthio)propanamide (40). General procedure VII was applied to
1275compound 17 (100 mg, 0.41 mmol), compound 30b (174 mg, 0.46
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1276 mmol), and Et3N (115 μL, 0.82 mmol) dissolved in anhydrous DMF
1277 (2 mL). Compound 40 was aﬀorded after silica gel column
1278 chromatography (petroleum ether/EtOAc 5:5) as a white sticky
1279 solid (83 mg, 41%). Rf = 0.73 (petroleum ether/EtOAc 5:5). IR
1280 (ATR) ν = 3505, 3323, 2919, 2851, 1640, 1519 cm−1. 1H NMR (400
1281 MHz, CDCl3) δ = 0.88 (t, 3H, J = 6.9 Hz, CH3), 1.23−1.37 (m, 22H,
1282 CH2), 1.51−1.61 (m, 2H, SCH2CH2), 2.01 (q, 4H, J = 6.4 Hz,
1283 CH2CH, CHCH2), 2.44−2.55 (m, 4H, COCH2, SCH2CH2), 2.83 (t,
1284 2H, J = 6.9 Hz, COCH2CH2), 3.88 (s, 3H, CH3O), 4.37 (d, 2H, J =
1285 5.7 Hz, CH2NH), 5.28−5.40 (m, 2H, CHCH), 5.64 (s, 1H, OH),
1286 5.94 (br s, 1H, CH2NH), 6.81 (ddd, 3H, J = 12.5, 9.9, 5.0 Hz, HAr).
1287
13C NMR (101 MHz, CDCl3) δ = 14.26 (CH3), 22.82 (CH2), 27.33
1288 (CH2CH), 27.36 (CHCH2), 28.03 (CH2S), 29.03 (CH2), 29.35
1289 (CH2), 29.39 (CH2), 29.46 (2 × CH2), 29.57 (CH2), 29.66 (CH2),
1290 29.76 (CH2), 29.88 (CH2), 29.91 (CH2), 32.04 (CH2), 32.61
1291 (COCH2), 37.08 (SCH2CH2), 43.77 (CH2NH), 56.11 (CH3O),
1292 110.80 (CAr), 114.49 (CAr), 120.93 (CAr), 129.93 (CHCH), 130.11
1293 (CHCH), 130.21 (CAr), 145.27 (CAr), 146.83 (CAr), 171.13
1294 (NHCO). HR-MS (ESI+), m/z: [M + H]+ calcd for C29H50NO3S,
g 1295 492.3511; found 492.3502.
1296 N-(4′-Hydroxy-3′-methoxybenzyl)-3-(octadeca-(9″Z,12″Z)-
1297 dien-1-ylthio)propanamide (41). General procedure VII was
1298 applied to compound 17 (100 mg, 0.41 mmol), compound 30c
1299 (173 mg, 0.46 mmol), and Et3N (115 μL, 0.82 mmol) dissolved in
1300 anhydrous DMF (2 mL). Compound 41 was aﬀorded after silica gel
1301 column chromatography (petroleum ether/EtOAc 7:3) as a yellow oil
1302 (110 mg, 55%). Rf = 0.66 (petroleum ether/EtOAc 5:5). IR (ATR) ν
1303 = 2923, 2854, 1643, 1515, 1273 cm−1. 1H NMR (400 MHz, CDCl3) δ
1304 = 0.89 (t, 3H, J = 6.9 Hz, CH3), 1.25−1.39 (m, 16H, CH2), 1.51−
1305 1.62 (m, 2H, SCH2CH2), 2.04 (q, 4H, J = 6.4 Hz, CH2CH, CHCH2),
1306 2.42−2.59 (m, 4H, SCH2CH2), 2.69−2.90 (m, 4H, COCH2CH2,
1307 CHCH2CH), 3.87 (s, 3H, CH3O), 4.36 (d, 2H, J = 5.7 Hz, CH2NH),
1308 5.26−5.43 (m, 4H, 2 × CHCH), 5.66 (s, 1H, OH), 5.96 (s, 1H,
1309 CH2NH), 6.80 (ddd, 3H, J = 12.5, 9.9, 5.0 Hz, HAr).
13C NMR (101
1310 MHz, CDCl3) δ = 14.21 (CH3), 22.71 (CH2), 25.77 (CHCH2CH),
1311 27.34 (CH2CH), 27.35 (CHCH2), 28.02 (CH2S), 29.02 (CH2), 29.34
1312 (CH2), 29.38 (CH2), 29.48 (CH2), 29.56 (CH2), 29.78 (CH2), 29.66
1313 (CH2), 31.59 (CH2), 32.59 (COCH2), 37.03 (SCH2CH2), 43.77
1314 (CH2NH), 56.10 (CH3O), 110.80 (CAr), 114.49 (CAr), 120.92 (CAr),
1315 128.04 (CHCH), 128.14 (CHCH), 130.19 (CAr), 130.22 (CH
1316 CH), 130.34 (CHCH), 145.27 (CAr), 146.83 (CAr), 171.14
1317 (NHCO). HR-MS (ESI+), m/z: [M + H]+ calcd for C29H48NO3S,
g 1318 490.3355; found 490.3351.
1319 Hexadecyl 2-[(3′-((4″-Hydroxy-3″-methoxybenzyl)amino)-
1320 3′-oxopropyl)thio]acetate (42). General procedure VII was
1321 applied to compound 17 (50 mg, 0.21 mmol), compound 32 (95
1322mg, 0.23 mmol), and Et3N (60 μL, 0.42 mmol) dissolved in
1323anhydrous DMF (2 mL). Compound 42 was aﬀorded after silica gel
1324column chromatography (petroleum ether/EtOAc 6:4) as a white
1325solid (75 mg, 68%). Mp: 59−60 °C. Rf = 0.61 (petroleum ether/
1326EtOAc 5:5). IR (ATR) ν = 3370, 3278, 2955, 2917, 2849, 1726, 1269
1327cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.88 (t, J = 6.9 Hz, 3H, CH3),
13281.24−1.33 (m, 26H, CH2), 1.57−1.65 (m, 2H, COOCH2CH2), 2.53
1329(t, 2H, J = 6.9 Hz, COCH2), 2.97 (t, 2H, J = 6.9 Hz, COCH2CH2),
13303.24 (s, 2H, SCH2), 3.88 (s, 3H, CH3OH), 4.06 (t, 2H, J = 6.9 Hz,
1331COOCH2CH2), 4.37 (d, 2H, J = 5.7 Hz, CH2NH), 5.63 (br s, 1H,
1332OH), 6.09 (br s, 1H, CH2NH), 6.80 (ddd, 3H, J = 12.5, 9.9, 5.0 Hz,
1333HAr).
13C NMR (101 MHz, CDCl3) δ = 14.26 (CH3), 22.83 (CH2),
133425.96 (CH2), 28.65 (CH2), 29.26 (CH2S), 29.36 (CH2), 29.50 (CH2),
133529.65 (CH2), 29.72 (CH2), 29.79 (CH2), 29.79 (CH2), 29.82 (CH2),
133629.83 (3 × CH2), 32.06 (CH2), 34.40 (SCH2), 36.55 (COCH2),
133743.76 (CH2NH), 56.12 (CH3O), 65.91 (COOCH2), 110.77 (CAr),
1338114.44 (CAr), 120.91 (CAr), 130.22 (CAr), 145.23 (CAr), 146.83 (CAr),
1339170.75 (NHCO), 170.80 (COOCH2). HR-MS (ESI
+), m/z: [M +
1340 gH]+ calcd for C29H50NO5S, 524.3404; found 524.3437.
1341N-(4′-Hydroxy-3′-methoxybenzyl)-3-[(((12″R)-tert-butyl-
1342dimethylsilyl)oxy)octadec-(9″Z)-en-1-ylthio]propanamide
1343(43). General procedure VII was applied to compound 17 (100 mg,
13440.41 mmol), compound 35 (236 mg, 0.46 mmol), and Et3N (120 μL,
13450.82 mmol) dissolved in DMF (2 mL). Compound 43 was aﬀorded
1346after silica gel column chromatography (petroleum ether/EtOAc 5:5)
1347as a yellow oil (135 mg, 53%). Rf = 0.45 (petroleum ether/EtOAc
13485:5). [α]D
20 −4.71 (c 0.45, DCM). IR (ATR) ν = 3370, 3278, 2955,
13492917, 2849, 1726, 1269 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.03
1350(s, 6H, Si(CH3)2), 0.73−0.94 (m, 12H, SiC(CH3)3, CH3), 1.14−1.42
1351(m, 20H, CH2), 1.47−1.67 (m, 2H, SCH2CH2), 2.00 (q, 2H, J = 6.4
1352Hz, CH2CH), 2.11−2.26 (m, 2H, CHCH2), 2.41−2.57 (m, 4H,
1353COCH2, SCH2CH2), 2.83 (t, 2H, J = 6.9 Hz, COCH2CH2), 3.55−
13543.74 (m, 1H, CH2CHO), 3.86 (s, 3H, CH3O), 4.34 (d, 2H, J = 5.7
1355Hz, CH2NH), 5.27−5.51 (m, 2H, CHCH), 5.76 (s, 1H, OH), 6.03
1356(s, 1H, CH2NH), 6.79 (ddd, 3H, J = 12.5, 9.9, 5 Hz, HAr).
13C NMR
1357(101 MHz, CDCl3) δ = 4.57 (SiCH3), −4.36 (SiCH3), 14.09 (CH3),
135818.13 (SiC(CH3)3), 22.62 (CH2), 25.38 (CH2), 25.91 (SiC(CH3)3),
135927.44 (CH2CH), 27.87 (CH2S), 28.87 (CH2), 29.20 (CH2), 29.28
1360(CH2), 29.44 (CH2), 29.46 (CH2), 29.60 (CH2), 29.65 (CH2), 31.87
1361(CH2), 32.43 (CH2), 35.24 (CHCH2), 36.84 (COCH2, SCH2CH2),
136243.59 (CH2NH), 55.93 (CH3O), 72.38 (CH2CHO), 110.66 (CAr),
1363114.36 (CAr), 120.74 (CAr), 125.93 (CHCH), 130.02 (CAr), 131.34
1364(CHCH), 145.12 (CAr), 146.71 (CAr), 171.04 (NHCO). HR-MS
1365(ESI+), m/z: [M + H]+ calcd for C35H64NO4SSi, 622.4307; found
1366 g622.4307.
1367N-(4′-Hydroxy-3′-methoxybenzyl)-3-[((12″R)-hydroxy)-
1368octadec-(9″Z)-en-1-ylthio]propanamide (44). General procedure
1369VIII was applied to compound 43 (100 mg, 0.16 mmol) in AcOH/
1370THF/H2O (1 mL, 6:2:2). Compound 44 was aﬀorded after silica gel
1371column chromatography (petroleum ether/EtOAc 6:4) as a colorless
1372oil (66 mg, 81%). Rf = 0.62 (petroleum ether/EtOAc 5:5). [α]D
20
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1373 −1.37 (c 0.4, DCM). IR (ATR) ν = 3290, 2923, 2852, 1645, 1514,
1374 1273 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.88 (t, 3H, J = 6.9 Hz,
1375 CH3), 1.21−1.38 (m, 18H, CH2), 1.41−1.49 (m, 4H, CH2), 1.51−
1376 1.60 (m, 2H, SCH2CH2), 2.04 (q, 2H, J = 6.4 Hz, CH2CH), 2.22 (t,
1377 2H, J = 6.9 Hz, CHCH2), 2.43−2.55 (m, 4H, COCH2, SCH2CH2),
1378 2.83 (t, 2H, J = 6.9 Hz, COCH2CH2), 3.56−3.65 (m, 1H, CH2CHO),
1379 3.88 (s, 3H, CH3O), 4.37 (d, 2H, J = 5.7 Hz, CH2NH), 5.34−5.46
1380 (m,1H, CHCH), 5.50−5.60 (m, 1H, CHCH), 6.00 (s, 1H,
1381 CH2NH), 6.80 (ddd, 3H, J = 12.5, 9.9, 5.0 Hz, HAr).
13C NMR (101
1382 MHz, CDCl3) δ = 14.23 (CH3), 22.76 (CH2), 25.86 (CH2), 27.53
1383 (CH2CH), 28.04 (CH2S), 28.95 (CH2), 29.28 (CH2), 29.35 (CH2),
1384 29.49 (2 × CH2), 29.71 (CH2), 29.76 (CH2), 31.98 (CH2), 32.59
1385 (SCH2CH2), 35.49 (CHCH2), 36.98 (COCH2), 36.99 (SCH2CH2),
1386 43.81 (CH2NH), 56.12 (CH3O), 71.67 (CH2CHO), 110.83 (CAr),
1387 114.52 (CAr), 120.94 (CAr), 125.31 (CHCH), 130.13 (CAr), 133.59
1388 (CHCH), 145.30 (CAr), 146.86 (CAr), 171.25 (NHCO). HR-MS




1393 acetate (45). General procedure VII was applied to compound 17
1394 (100 mg, 0.41 mmol), compound 38 (255 mg, 0.46 mmol), and Et3N
1395 (115 μL, 0.82 mmol) dissolved in anhydrous DMF (2 mL).
1396 Compound 45 was aﬀorded after silica gel column chromatography
1397 (petroleum ether/EtOAc 6:4) as a yellow oil (51 mg, 20%). Rf = 0.78
1398 (petroleum ether/EtOAc 6:4). [α]D
20 7.90 (c 0.4, DCM). IR (ATR) ν
1399 = 3290, 2924, 2853, 1729, 1646, 1514 cm−1. 1H NMR (400 MHz,
1400 CDCl3) δ = 0.86 (t, 3H, J = 6.9 Hz, CH3), 1.06−1.40 (m, 18H, CH2),
1401 1.46−1.60 (m, 4H, CH2, SCH2CH2), 1.99 (q, 2H, J = 6.4 Hz,
1402 CH2CH), 2.19−2.35 (m, 2H, CHCH2), 2.44−2.56 (m, 4H, COCH2,
1403 SCH2CH2), 2.83 (t, 2H, J = 6.9 Hz, COCH2CH2), 3.58 (s, 2H,
1404 OCOCH2), 3.87 (s, 3H, CH3O), 4.36 (d, 2H, J = 5.7 Hz, CH2NH),
1405 4.86 (p, 1H, J = 6.2 Hz, CH2CHO), 5.22−5.32 (m, 1H, CHCH),
1406 5.39−5.48 (m, 1H, CHCH), 6.04 (br s, 1H, CH2NH), 6.80 (ddd,
1407 3H, J = 12.5, 9.9, 5.0 Hz, HAr), 7.21−7.34 (m, 5H, HAr). 13C NMR
1408 (101 MHz, CDCl3) δ = 14.20 (CH3), 22.66 (CH2), 25.33 (CH2),
1409 27.45 (CH2CH), 27.01 (CH2S), 28.99 (CH2), 29.20 (CH2), 29.32
1410 (CH2), 29.37 (CH2), 29.55 (CH2), 29.69 (CH2), 29.73 (CH2), 31.82
1411 (CH2), 32.04 (CHCH2), 32.57 (COCH2), 33.69 (CH2), 36.91
1412 (SCH2CH2), 41.90 (OCOCH2), 43.84 (CH2NH), 56.11 (CH3O),
1413 74.65 (CH2CHO), 110.81 (CAr), 114.50 (CAr), 120.94 (CAr), 124.25
1414 (CHCH), 127.09 (CAr), 128.60 (2 × CAr), 129.36 (2 × CAr),
1415 130.06 (CAr), 132.80 (CHCH), 134.46 (CAr), 145.30 (CAr), 146.84
1416 (CAr), 171.37 (NHCO), 171.48 (OCOCH2). HR-MS (ESI
+), m/z:
g 1417 [M + H]+ calcd for C37H56NO5S, 626.3879; found 626.3870.
1418 3-(Hexadecylseleno)-N-(4′-hydroxy-3′-methoxybenzyl)-
1419 propanamide (46). General procedure IV was applied to compound
1420 20 (100 mg, 0.32 mmol), NaBH4 (30 mg, 0.8 mmol), and compound
1421 30a (126 mg, 0.36 mmol) dissolved in EtOH (2 mL). Compound 46
1422 was aﬀorded after silica gel column chromatography (petroleum
1423ether/EtOAc 7:3) as a yellow sticky solid (166 mg, 71%). Rf = 0.55
1424(petroleum ether/EtOAc 7:3). IR (ATR) ν = 3504, 3317, 2917, 2848,
14251645, 1519 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.88 (t, 3H, J =
14266.9 Hz, CH3), 1.22−1.36 (m, 26H, CH2), 1.59−1.68 (m, 2H,
1427SeCH2CH2), 2.53−2.62 (m, 4H, COCH2, SeCH2CH2), 2.83 (t, 2H, J
1428= 6.9 Hz, CH2Se), 3.88 (s, 3H, CH3O), 4.36 (d, 2H, J = 5.7 Hz,
1429CH2NH), 5.66 (s, 1H, CH2NH), 5.88 (br s, 1H, OH), 6.80 (ddd, 3H,
1430J = 12.5, 9.9, 5.0 Hz, HAr).
13C NMR (101 MHz, CDCl3) δ = 14.26
1431(CH3), 18.69 (CH2Se), 22.83 (CH2), 24.84 (SeCH2CH2), 29.31
1432(CH2), 29.49 (CH2), 29.68 (CH2), 29.75 (CH2), 29.79 (2 × CH2),
143329.83 (4 × CH2), 30.08 (CH2), 30.74 (CH2), 32.06 (CH2), 38.03
1434(COCH2), 43.78 (CH2NH), 56.12 (CH3O), 110.83 (CAr), 114.49
1435(CAr), 120.96 (CAr), 130.20 (CAr), 145.28 (CAr), 146.84 (CAr), 171.41
1436(NHCO). HR-MS (ESI+), m/z: [M + H]+ calcd for C27H48NO3Se,
1437 g514.2799; found 514.2795.
1438N-(4′-Hydroxy-3′-methoxybenzyl)-3-(octadec-(9″Z)-en-1-
1439ylseleno)propanamide (47). General procedure IV was applied to
1440compound 20 (200 mg, 0.64 mmol), NaBH4 (59 mg, 1.6 mmol), and
1441compound 30b (271 mg, 0.72 mmol) dissolved in EtOH (2 mL).
1442Compound 47 was aﬀorded after silica gel column chromatography
1443(petroleum ether/EtOAc 7:3) as a yellow sticky solid (244 mg, 71%).
1444Rf = 0.71 (petroleum ether/EtOAc 7:3). IR (ATR) ν = 3509, 3321,
14452919, 2850, 1646, 1519 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.88
1446(t, 3H, J = 6.9 Hz, CH3), 1.24−1.37 (m, 22H, CH2), 1.60−1.68 (m,
14472H, SeCH2CH2), 2.01 (q, 4H, J = 6.4 Hz, CH2CH, CHCH2), 2.54−
14482.61 (m, 4H, COCH2, SeCH2CH2), 2.84 (t, 2H, J = 6.9 Hz,
1449COCH2CH2), 3.88 (s, 3H, CH3O), 4.37 (d, 2H, J = 5.7 Hz,
1450CH2NH), 5.29−5.40 (m, 2H, CHCH), 5.61 (s, 1H, OH), 5.83 (br
1451s, 1H, CH2NH), 6.82 (ddd, 3H, J = 12.5, 9.9, 5.0 Hz, HAr).
13C NMR
1452(101 MHz, CDCl3) δ = 14.27 (CH3), 18.70 (CH2Se), 22.83 (CH2),
145324.84 (SeCH2CH2), 27.35 (CH2CH), 27.37 (CHCH2), 29.29 (CH2),
145429.40 (CH2), 29.47 (2 × CH2), 29.58, (CH2) 29.67 (CH2), 29.89
1455(CH2), 29.92 (CH2), 30.08 (CH2), 30.74 (CH2), 32.05 (CH2), 38.06
1456(COCH2), 43.80 (CH2NH), 56.14 (CH3O), 110.83 (CAr), 114.48
1457(CAr), 120.99 (CAr), 129.94 (CHCH), 130.11 (CHCH), 130.22
1458(CAr), 145.29 (CAr), 146.84 (CAr), 171.37 (NHCO). HR-MS (ESI
+),
1459 gm/z: [M + H]+ calcd for C29H50NO3Se, 540.2956; found 540.2957.
1460N-(4′-Hydroxy-3′-methoxybenzyl)-3-(octadeca-(9″Z,12″Z)-
1461dien-1-ylseleno)propanamide (48). General procedure IV was
1462applied to compound 20 (100 mg, 0.32 mmol), NaBH4 (30 mg, 0.80
1463mmol), and compound 30c (135 mg, 0.36 mmol) dissolved in EtOH
1464(2 mL). Compound 48 was aﬀorded after silica gel column
1465chromatography (petroleum ether/EtOAc 7:3) as a yellowish oil
1466(111 mg, 65%). Rf = 0.7 (petroleum ether/EtOAc 7:3). IR (ATR) ν =
14673288, 3008, 2923, 2852, 1644, 1514 cm−1. 1H NMR (400 MHz,
1468CDCl3) δ = 0.88 (t, 3H, J = 6.9 Hz, CH3), 1.25−1.38 (m, 16H, CH2),
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1469 1.59−1.68 (m, 2H, SeCH2CH2), 2.04 (q, 4H, J = 6.4 Hz, CH2CH,
1470 CHCH2), 2.54−2.61 (m, 4H, COCH2, SeCH2CH2), 2.77 (t, 2H, J =
1471 6.9 Hz, 2H, CHCH2CH), 2.83 (t, 2H, J = 6.9 Hz, COCH2CH2), 3.88
1472 (s, 3H, CH3O), 4.36 (d, 2H, J = 5.7 Hz, CH2NH), 5.28−5.42 (m, 4H,
1473 2 × CHCH), 5.66 (s, 1H, OH), 5.88 (br s, 1H, CH2NH), 6.80
1474 (ddd, 3H, J = 12.5, 9.9, 5.0 Hz, HAr).
13C NMR (101 MHz, CDCl3) δ
1475 = 14.21 (CH3), 18.69 (CH2), 22.70 (CH2), 24.81 (SeCH2CH2), 25.77
1476 (CHCH2CH), 27.33 (CH2CH), 27.35 (CHCH2), 29.26 (CH2), 29.38
1477 (CH2), 29.48 (CH2), 29.56 (CH2), 29.77 (CH2), 30.06 (CH2), 30.72
1478 (CH2), 31.66 (CH2), 38.02 (COCH2), 43.78 (CH2NH), 56.12
1479 (CH3O), 110.82 (CAr), 114.48 (CAr), 120.95 (CAr), 128.04 (CH
1480 CH), 128.14 (CHCH), 130.19 (CAr), 130.22 (CHCH), 130.34
1481 (CHCH), 145.28 (CAr), 146.83 (CAr), 171.39 (NHCO). HR-MS




1486 propanamide (49). General procedure IV was applied to compound
1487 20 (100 mg, 0.32 mmol), NaBH4 (30 mg, 0.80 mmol), and
1488 compound 35 (233 mg, 0.46 mmol) dissolved in EtOH (2 mL).
1489 Compound 49 was aﬀorded after silica gel column chromatography
1490 (petroleum ether/EtOAc 7:3) as a yellow oil (124 mg, 58%). Rf =
1491 0.54 (petroleum ether/EtOAc 7:3). [α]D
20 −2.21 (c 0.7, DCM). IR
1492 (ATR) ν = 3288, 2924, 2853, 1645, 1514. 1H NMR (400 MHz,
1493 CDCl3) δ = 0.04 (s, 6H, Si(CH3)2), 0.80−0.97 (m, 12H, SiC(CH3)3,
1494 CH3), 1.15−1.32 (m, 20H, CH2), 1.52−1.71 (m, 2H, SeCH2CH2),
1495 2.01 (q, 2H, J = 6.4 Hz, CH2CH), 2.18 (t, 2H, J = 6.9 Hz, CHCH2),
1496 2.58 (t, 4H, J = 6.9 Hz, COCH2, SeCH2CH2), 2.84 (s, 2H,
1497 COCH2CH2), 3.58−3.70 (m, 1H, CH2CHO), 3.89 (s, 3H, CH3O),
1498 4.37 (d, 2H, J = 5.7 Hz, CH2NH), 5.32−5.49 (m, 2H, CHCH),
1499 5.58 (s, 1H, OH), 5.80 (s, 1H, CH2NH), 6.81 (ddd, 3H, J = 12.5, 9.9,
1500 5.0 Hz, HAr).
13C NMR (101 MHz, CDCl3) δ = −4.56 (SiCH3),
1501 −4.36 (SiCH3), 14.09 (CH3), 18.14 (SiC(CH3)3), 18.55 (CH2Se),
1502 22.62 (CH2), 24.71 (SeCH2CH2), 25.39 (CH2), 25.91 (SiC(CH3)3),
1503 27.45 (CH2CH), 29.13 (CH2), 29.29 (CH2), 29.44 (CH2), 29.46
1504 (CH2), 29.65 (CH2), 29.68 (CH2), 29.93 (CH2), 31.88 (CH2), 35.25
1505 (CHCH2), 36.85 (CH2), 37.90 (COCH2), 43.64 (CH2NH), 55.97
1506 (CH3O), 72.39 (CH2CHO), 110.65 (CAr), 114.31 (CAr), 120.83
1507 (CAr), 125.93 (CHCH), 130.05 (CAr), 131.35 (CHCH), 145.12
g 1508 (CAr), 146.66 (CAr), 171.19 (NHCO).
1509 N-(4′-Hydroxy-3′-methoxybenzyl)-3-[((12″R)-hydroxy)-
1510 octadec-(9″Z)-en-1-ylseleno]propanamide (50). General proce-
1511 dure VIII was applied to compound 49 (100 mg, 0.18 mmol) in
1512 AcOH/THF/H2O (1 mL, 6:2:2). Compound 50 was aﬀorded after
1513 silica gel column chromatography (petroleum ether/EtOAc 5:5) as a
1514 pale yellow oil (79 mg, 79%). Rf = 0.77 (petroleum ether/EtOAc 7:3).
1515 [α]D
20 −7.88 (c 0.3, DCM). IR (ATR) ν = 3288, 2923, 2852, 1646,
1516 1514 1273 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.88 (t, 3H, J =
1517 6.9 Hz, CH3), 1.21−1.39 (m, 18H, CH2), 1.42−1.48 (m, 2H,
1518 COHCH2), 1.58−1.67 (m, 2H, SeCH2CH2), 2.04 (q, 2H, J = 6.4 Hz,
1519 CH2CH), 2.20 (t, 2H, J = 6.9 Hz, CHCH2), 2.53−2.61 (m, 4H,
1520COCH2, SeCH2CH2), 2.83 (t, 2H, J = 6.9 Hz, COCH2CH2), 3.57−
15213.65 (m, 1H, CH2CHO), 3.87 (s, 3H, CH3O), 4.36 (d, 2H, J = 5.7
1522Hz, CH2NH), 5.34−5.45 (m, 1H, CHCH), 5.49−5.60 (m, 1H,
1523CHCH), 5.73 (br s, 1H, OH), 5.93 (br s, 1H, CH2NH), 6.80 (ddd,
15243H, J = 12.5, 9.9, 5.0 Hz, HAr).
13C NMR (101 MHz, CDCl3) δ =
152514.23 (CH3), 18.71 (CH2Se), 22.76 (CH2), 24.81 (SeCH2CH2),
152625.86 (CH2), 27.53 (CH2), 29.21 (CH2), 29.35 (CH2), 29.49 (2 ×
1527CH2), 29.75 (CH2), 30.00 (CH2), 30.69 (SeCH2CH2), 31.98 (CH2),
152835.50 (CHCH2), 36.98 (CH2), 38.04 (COCH2), 43.79 (CH2NH),
152956.13 (CH3O), 71.65 (CH2CHO), 110.85 (CAr), 114.51 (CAr),
1530120.97 (CAr), 125.31 (CHCH), 130.21 (CAr), 133.58 (CHCH),
1531145.29 (CAr), 146.85 (CAr), 171.39 (NHCO). HR-MS (ESI
+), m/z:
1532 g[M + H]+ calcd for C29H50NO4Se, 556.2905; found 556.2901.
15331″-Hexyl-12″-[(3‴-((4⁗-hydroxy-3⁗-methoxybenzyl)-
1534amino)-3‴-oxopropyl)seleno]dodec-(3″Z)-en-(1″R)-yl 2-phe-
1535nylacetate (51). General procedure IV was applied to compound
153620 (100 mg, 0.32 mmol), NaBH4 (30 mg, 0.80 mmol), and
1537compound 38 (200 mg, 0.36 mmol) dissolved in EtOH (2 mL).
1538Compound 51 was aﬀorded after silica gel column chromatography
1539(petroleum ether/EtOAc 5:5) as a yellow oil (155 mg, 72%). Rf =
15400.58 (petroleum ether/EtOAc 5:5). [α]D
20 14.78 (c 1.8, DCM). IR
1541(ATR) ν = 3291, 2924, 2853, 1729, 1645, 1514 cm−1. 1H NMR (400
1542MHz, CDCl3) δ = 0.89 (t, 3H, J = 6.9 Hz, CH3), 1.20−1.40 (m, 18H,
1543CH2), 1.50−1.58 (m, 2H, SeCH2CH2), 1.61−1.71 (m, 2H,
1544COHCH2), 2.01 (q, 2H, J = 6.4 Hz, CH2CH), 2.23−2.37 (m, 2H,
1545CHCH2), 2.60 (t, 4H, J = 6.9 Hz, COCH2, SeCH2CH2), 2.86 (t, 2H,
1546J = 6.9 Hz, COCH2CH2), 3.61 (s, 2H, OCOCH2), 3.89 (s, 3H,
1547CH3O), 4.38 (d, 2H, J = 5.7 Hz, CH2NH), 4.90 (p, 1H, J = 6.3 Hz,
1548CH2CHO), 5.26−5.35 (m, 1H, CHCH), 5.42−5.51 (m, 1H,
1549CHCH), 5.75 (s, 1H, OH), 5.98 (br s, 1H, CH2NH), 6.83 (ddd,
15503H, J = 12.5, 9.9, 5.0 Hz, HAr), 7.16−7.42 (m, 5H, HAr). 13C NMR
1551(101 MHz, CDCl3) δ = 14.18 (CH3), 18.68 (CH2), 22.63 (CH2),
155224.76 (SeCH2CH2), 25.30 (CH2), 27.43 (CH2CH), 29.18 (CH2),
155329.23 (CH2), 29.35 (CH2), 29.53 (CH2), 29.66 (CH2), 30.02 (CH2),
155430.68 (CH2), 31.79 (CH2), 32.01 (CHCH2), 33.66 (CH2), 37.97
1555(COCH2), 41.87 (OCOCH2), 43.74 (CH2NH), 56.09 (CH3O),
155674.62 (CH2CHO), 110.82 (CAr), 114.48 (CAr), 120.91 (CAr), 124.22
1557(CHCH), 127.06 (CAr), 128.57 (2 × CAr), 129.33 (2 × CAr),
1558130.17 (CAr), 132.78 (CHCH), 134.42 (CAr), 145.26 (CAr), 146.83
1559(CAr), 171.41 (NHCO), 171.46 (OCOCH2). HR-MS (ESI
+), m/z:
1560 g[M + H]+ calcd for C37H56NO5Se, 674.3324; found 674.3315.
1561(2R)-Boc-amino-3-(hexadecylthio)-N-(4′-hydroxy-3′-
1562methoxybenzyl)propanamide (52). General procedure VII was
1563applied to compound 24 (200 mg, 0.56 mmol), compound 30a (220
1564mg, 0.63 mmol), and Et3N (0.16 mL, 1.12 mmol) in anhydrous DMF
1565(5 mL). Compound 52 was aﬀorded after silica gel column
1566chromatography (petroleum ether/EtOAc 6:4) as a white solid
1567(230 mg, 71%). Rf = 0.29 (petroleum ether/EtOAc 5:5). Mp: 76−77
1568°C. [α]D
20 −2.28 (c 0.6, DCM). IR (ATR) ν = 3449, 3336, 2918, 2850,
15691681, 1659, 1513 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.87 (t, 3H,
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1570 J = 6.9 Hz, CH3), 1.15−1.35 (m, 26H, CH2), 1.42 (s, 9H, C(CH3)3),
1571 1.47−1.60 (m, 2H, SCH2CH2), 2.52 (td, 2H, J = 6.9, 1.7 Hz,
1572 SCH2CH2), 2.84 (dd, 1H, J = 13.7, 6.9 Hz, CHCH2S), 2.98 (dd, 1H J
1573 = 13.7, 5.5 Hz, CHCH2S), 3.86 (s, 3H, CH3O), 4.25 (d, 1H, J = 5.7
1574 Hz, CH2NH), 4.29−4.45 (m, 2H, CHCH2S), 5.39 (d, 1H, J = 5.7 Hz,
1575 CH2NH), 5.70 (s, 1H, OH), 6.67 (t, J = 5.5 Hz, 1H, NHBoc), 6.78
1576 (ddd, 3H, J = 12.5, 9.9, 5.0 Hz, HAr).
13C NMR (101 MHz, CDCl3) δ
1577 = 14.25 (CH3), 22.82 (CH2), 28.39 (C(CH3)3), 28.92 (CH2), 29.36
1578 (CH2), 29.49 (CH2), 29.65 (CH2), 29.74 (CH2), 29.78 (2 × CH2),
1579 29.81 (CH2), 29.82 (4 × CH2), 32.05 (CH2), 32.82 (SCH2CH2),
1580 34.61 (CHCH2S), 43.68 (CH2NH), 54.25 (CHCH2S), 56.08
1581 (CH3O), 80.59 (C(CH3)3), 110.63 (CAr), 114.50 (CAr), 120.76
1582 (CAr), 129.81 (CAr), 145.24 (CAr), 146.83 (CAr), 155.51 (NHCO2),
1583 170.58 (NHCO). HR-MS (ESI+), m/z: [M + H]+ calcd for
g 1584 C32H57N2O5S, 581.3988; found 581.3978.
1585 (2R)-Boc-amino-N-(4′-hydroxy-3′-methoxybenzyl)-3-(octa-
1586 dec-(9″Z)-en-1-ylthio)propanamide (53). General procedure VII
1587 was applied to compound 24 (100 mg, 0.42 mmol), compound 30b
1588 (179 mg, 0.47 mmol), and Et3N (117 μL mL, 0.84 mmol) dissolved
1589 in DMF (2 mL). Compound 53 was aﬀorded after silica gel column
1590 chromatography (petroleum ether/EtOAc 7:3) as a white solid (127
1591 mg, 50%). Mp: 43−44 °C. Rf = 0.58 (petroleum ether/EtOAc 7:3).
1592 [α]D
20 0.26 (c 1.2, DCM). IR (ATR) ν = 3450, 3333, 2918, 2850,
1593 1514, 1240 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.88 (t, 3H, J =
1594 6.9 Hz, CH3), 1.18−1.38 (m, 22H, CH2), 1.42 (s, 9H, C(CH3)3),
1595 1.48−1.61 (m, 2H, SCH2CH2), 2.01 (q, 4H, J = 6.4 Hz, CH2CH,
1596 CHCH2), 2.45−2.58 (m, 2H, SCH2CH2), 2.84 (dd, 1H, J = 13.7, 6.9
1597 Hz, CHCH2S), 3.00 (dd, 1H, J = 13.7, 5.5 Hz, CHCH2S), 3.88 (s,
1598 3H, CH3O), 4.24 (dd, 1H, J = 12.5, 6.1 Hz CH2NH), 4.30−4.48 (m,
1599 2H, CHCH2S), 5.22−5.44 (m, 3H, CHCH, CH2NH), 5.59 (s, 1H,
1600 OH), 6.61 (t, 1H, J = 5.5 Hz, NHBoc), 6.80 (ddd, 3H, J = 12.5, 9.9,
1601 5.0 Hz, HAr).
13C NMR (101 MHz, CDCl3) δ = 14.10 (CH3), 22.66
1602 (CH2), 27.18 (CH2CH), 27.20 (CHCH2), 28.24 (C(CH3)3), 28.76
1603 (CH2), 29.18 (CH2), 29.23 (CH2), 29.29 (CH2), 29.30 (CH2), 29.40
1604 (SCH2CH2), 29.50 (CH2), 29.59 (CH2), 29.68 (CH2), 29.73 (CH2),
1605 29.75 (CH2), 31.88 (CH2), 32.66 (SCH2CH2), 34.44 (CHCH2S),
1606 43.55 (CH2NH), 54.12 (CHCH2S), 55.94 (CH3O), 80.57
1607 (C(CH3)3), 110.45 (CAr), 114.31 (CAr), 120.64 (CAr), 129.68
1608 (CAr), 129.76 (CHCH), 129.95 (CHCH), 145.10 (CAr),
1609 146.65 (CAr), 155.55 (NHCO2), 170.37 (NHCO). HR-MS (ESI
+),
g 1610 m/z: [M + H]+ calcd for C34H59N2O5S, 607.4145; found 607.4138.
1611 Hexadecyl 2-[((2′R)-Boc-amino-3′-((4″-hydroxy-3″-
1612 methoxybenzyl)amino)-3′-oxopropyl)thio]acetate (54). Gener-
1613 al procedure VII was applied to compound 24 (200 mg, 0.56 mmol),
1614 compound 35 (258 mg, 0.63 mmol), and Et3N (160 μL, 1.12 mmol)
1615 dissolved in anhydrous DMF (2 mL). Compound 54 was aﬀorded
1616after silica gel column chromatography (petroleum ether/EtOAc 7:3)
1617as a white solid (282 mg, 79%). Mp: 74−75 °C. Rf = 0.75 (petroleum
1618ether/EtOAc 7:3). [α]D
20 −8.04 (c 1, MeOH). IR (ATR) ν = 3493,
16193326, 2917, 2849, 1655, 1518 cm−1. 1H NMR (400 MHz, CDCl3) δ =
16200.88 (t, J = 6.9 Hz, 3H, CH3), 1.17−1.35 (m, 26H, CH2), 1.42 (s, 9H,
1621C(CH3)3), 1.55−1.65 (m, 2H, COOCH2CH2), 2.88 (dd, 1H, J =
162213.7, 6.9 Hz, CHCH2S), 3.07 (dd, 1H, J = 13.7, 6.9 Hz, CHCH2S),
16233.35 (s, 2H, SCH2), 3.87 (s, 3H, CH3OH), 4.07 (t, 2H, J = 6.9 Hz,
1624COOCH2CH2), 4.25−4.49 (m, 3H, COCHCH2, CH2NH), 5.47−
16255.69 (m, 2H, CH2NH, OH), 6.73−6.87 (m, 3H, HAr), 7.04 (t, 1H, J =
16265.0 Hz, NHBoc). 13C NMR (101 MHz, CDCl3) δ = 14.09 (CH3),
162722.66 (CH2), 25.78 (CH2), 28.26 (C(CH3)3), 28.44 (CH2), 29.20
1628(CH2), 29.33 (CH2), 29.48 (CH2), 29.55 (CH2), 29.62 (CH2), 29.63
1629(CH2), 29.65 (CH2), 29.67 (3 × CH2), 31.90 (CH2), 34.70
1630(SCH2CH2), 35.89 (CHCH2S), 43.50 (CH2NH), 53.59 (CHCH2S),
163155.93 (CH3O), 66.07 (COOCH2), 80.35 (C(CH3)3), 110.42 (CAr),
1632114.28 (CAr), 120.61 (CAr), 129.70 (CAr), 145.00 (CAr), 146.62 (CAr),
1633155.46 (NHCO2), 170.00 (NHCO), 171.34 (COOCH2). HR-MS
1634(ESI+), m/z: [M + H]+ calcd for C34H59N2O7S, 639.4043; found
1635 g639.4040.
16362-(Hexadecylthio)-1-[N-(4′-hydroxy-3′-methoxybenzyl)-
1637carbamoyl]-(1R)-ethylammonium Triﬂuoroacetate (55). Gen-
1638eral procedure IX was applied to compound 52 (200 mg, 0.34 mmol),
1639TFA (0.26 mL, 3.4 mmol) in DCM (1 mL). Compound 55 was
1640aﬀorded after ﬂushing nitrogen and drying in vacuo as a yellow oil
1641(195 mg, quantitative). [α]D
20 −6.67 (c 0.6, DCM). IR (ATR) ν =
16423093, 2921, 2852, 1779, 1667, 1153 cm−1. 1H NMR (400 MHz,
1643CDCl3) δ = 0.88 (t, 3H, J = 6.9 Hz, CH3), 1.21−1.31 (m, 26H, CH2),
16441.45−1.54 (m, 2H, SCH2CH2), 2.48 (t, 2H, J = 6.9 Hz, SCH2CH2),
16452.85−3.03 (m, 2H, CHCH2S), 3.83 (s, CH3O), 4.22−4.38 (m, 3H,
1646CHCH2S, CH2NH), 6.52 (br s, 2H, NH2), 6.68−6.85 (m, 4H, OH,
1647HAr), 7.55 (t, 1H, J = 5.0 Hz, CH2NH).
13C NMR (101 MHz,
1648CDCl3) δ = 14.26 (CH3), 22.85 (CH2), 28.82 (CH2), 29.30 (CH2),
164929.32 (CH2), 29.52 (CH2), 29.65 (CH2), 29.74 (2 × CH2), 29.84
1650(CH2), 29.86 (4 × CH2), 32.08 (CH2), 32.50 (SCH2CH2), 33.06
1651(CHCH2S), 44.38 (CH2NH), 52.72 (CHCH2S), 56.01 (CH3O),
1652110.67 (CAr), 114.71 (CAr), 116.86 (CF3COOH), 120.92 (CAr),
1653128.31 (CAr), 145.52 (CAr), 146.95 (CAr), 161.37 (CF3COOH),
1654167.54 (NHCO). HR-MS (ESI+), m/z: [M + H]+ calcd for
1655 gC27H49N2O3S, 481.3458; found 481.3497.
16561-[N-(4′-Hydroxy-3′-methoxybenzyl)carbamoyl]-2-(octa-
1657dec-(9″Z)-en-1-ylthio)-(1R)-ethylammonium Triﬂuoroacetate
1658(56). General procedure IX was applied to compound 53 (100 mg,
16590.16 mmol), TFA (120 μL, 1.64 mmol) in DCM (1 mL). Compound
166056 was aﬀorded after ﬂushing nitrogen and drying in vacuo as a yellow
1661oil (98 mg, quantitative). [α]D
20 0.62 (c 2.2, DCM). IR (ATR) ν =
16622922, 2853, 1662, 1199, 1133 cm−1. 1H NMR (400 MHz, CDCl3) δ =
16630.87 (t, 3H, J = 6.9 Hz, CH3), 1.21−1.35 (m, 22H, CH2), 1.43−1.51
1664(m, 2H, SCH2CH2), 2.00 (q, 4H, J = 6.4 Hz, CH2CH, CHCH2), 2.45
1665(t, 2H, J = 6.9 Hz, SCH2CH2), 2.94 (d, 2H, J = 6.0 Hz, CHCH2S),
16663.78 (s, 3H, CH3O), 4.13−4.34 (m, 3H, CHCH2S, CH2NH), 5.26−
16675.43 (m, 2H, CHCH), 6.70 (ddd, 3H, J = 12.5, 9.9, 5.0 Hz, HAr),
16687.87 (t, 1H, J = 5.0 Hz, CH2NH).
13C NMR (101 MHz, CDCl3) δ =
166914.25 (CH3), 22.83 (CH2), 27.37 (CH2CH, CHCH2), 28.86 (CH2),
167029.34 (CH2), 29.41 (CH2), 29.44 (CH2), 29.46 (CH2), 29.47 (CH2),
167129.61 (CH2), 29.68 (CH2), 29.82 (CH2), 29.85 (CH2), 29.92 (CH2),
167232.05 (CH2), 32.66 (SCH2CH2), 32.96 (CHCH2S), 44.0 (CH2NH),
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1673 52.77 (CHCH2S), 55.96 (CH3O), 110.71 (CAr), 114.67 (CAr), 120.74
1674 (CAr), 128.82 (CAr), 129.90 (CHCH), 130.11 (CHCH), 145.27
1675 (CAr), 146.93 (CAr), 167.76 (NHCO). HR-MS (ESI
+), m/z: [M +
g 1676 H]+ calcd for C31H51N2O3S, 507.3615; found 507.3616.
1677 2′-Hexadecyloxy-1-[N-(4″-hydroxy-3″-methoxybenzyl)]-
1678 carbamoyl-2-[(oxoethyl)thio]ethan-(1R)-ammonium Triﬂuor-
1679 oacetate (57). General procedure IX was applied to compound 54
1680 (200 mg, 0.31 mmol), TFA (240 μL, 3.1 mmol) in DCM (1 mL).
1681 Compound 57 was aﬀorded after ﬂushing nitrogen and drying in
1682 vacuo as a yellow oil (201 mg, quantitative). [α]D
20 −7.53 (c 0.4,
1683 MeOH). IR (ATR) ν = 2917, 2850, 1662, 1176, 1131 cm−1. 1H NMR
1684 (400 MHz, CDCl3) δ = 0.88 (t, J = 6.9 Hz, 3H, CH3), 1.18−1.34 (m,
1685 26H, CH2), 1.53−1.64 (m, 2H, COOCH2CH2), 2.98−3.14 (m, 2H,
1686 CHCH2S), 3.37 (s, 2H, SCH2), 3.82 (s, 3H, CH3OH), 3.99−4.11 (m,
1687 2H, COOCH2CH2), 4.22−4.43 (m, 3H, COCHCH2, H2NH), 6.67−
1688 6.83 (m, 3H, HAr), 7.94 (t, 1H, J = 5.0 Hz, CH2NH).
13C NMR (101
1689 MHz, CDCl3) δ = 14.26 (CH3), 22.84 (CH2), 25.87 (CH2), 28.43
1690 (CH2), 29.35 (CH2), 29.51 (2 × CH2), 29.64 (CH2), 29.73 (CH2),
1691 29.81 (CH2), 29.83 (CH2), 29.85 (3 × CH2), 32.08 (CH2), 34.65
1692 (CH2), 34.95 (CH2), 44.24 (CH2NH), 53.08 (CHCH2S), 55.99
1693 (CH3O), 67.26 (COOCH2), 110.62 (CAr), 114.64 (CAr), 120.80
1694 (CAr), 128.61 (CAr), 145.35 (CAr), 146.91 (CAr), 167.33 (NHCO),
1695 172.72 (COOCH2). HR-MS (ESI
+), m/z: [M + H]+ calcd for
g 1696 C29H51N2O5S, 539.3513; found 539.3557.
1697 (2R)-Boc-amino-3-(hexadecylseleno)-N-(4′-hydroxy-3′-
1698 methoxybenzyl)propanamide (58). General procedure III was
1699 applied to compound 27 (200 mg, 0.25 mmol), NaBH4 (24 mg, 0.62
1700 mmol), and compound 30a (197 mg, 0.56 mmol) dissolved in EtOH
1701 (2 mL). Compound 58 was aﬀorded after silica gel column
1702 chromatography (petroleum ether/EtOAc 7:3) as a white solid
1703 (231 mg, 74%). Rf = 0.37 (petroleum ether/EtOAc 6:4). Mp: 75−76
1704 °C. [α]D20 −5.24 (c 1.3, DCM). IR (ATR) ν = 3281, 3008, 2924, 2854,
1705 1666, 1516 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.88 (t, 1H, J =
1706 6.9 Hz, CH3), 1.17−1.38 (m, 26H, CH2), 1.42 (s, 9H, J = 4.9 Hz,
1707 C(CH3)3), 1.58−1.69 (m, 2H, SeCH2CH2), 2.46−2.67 (m, 2H,
1708 SeCH2CH2), 2.83 (dd, 1H, J = 12.8, 6.9 Hz, CHCH2Se), 3.05 (dd,
1709 1H, J = 12.8, 5.2 Hz, CHCH2Se), 3.88 (s, 3H, CH3O), 4.22−4.36 (m,
1710 1H, CHCH2Se), 4.37 (d, 2H, J = 5.7 Hz, CH2NH), 5.33 (s, 1H,
1711 CH2NH), 5.58 (s, 1H, OH), 6.55 (t, 1H, J = 5.5 Hz, NHBoc), 6.80
1712 (ddd, 3H, J = 12.5, 9.9, 5.0 Hz, HAr).
13C NMR (101 MHz, CDCl3) δ
1713 = 14.10 (CH3), 22.67 (CH2), 25.37 (SeCH2CH2), 25.88 (CHCH2Se),
1714 28.24 (C(CH3)3), 29.13 (CH2), 29.34 (CH2), 29.51 (CH2), 29.59
1715 (CH2), 29.63 (3 × CH2), 29.66 (CH2), 29.67 (2 × CH2), 29.81
1716 (CH2), 30.51 (CH2), 31.90 (CH2), 43.54 (CH2NH), 54.63
1717 (CHCH2Se), 55.95 (CH3O), 80.37 (C(CH3)3), 110.49 (CAr),
1718 114.32 (CAr), 120.65 (CAr), 129.68 (CAr), 145.10 (CAr), 146.67
1719 (CAr), 155.30 (NHCO2), 170.46 (NHCO). HR-MS (ESI
+), m/z: [M
g 1720 + H]+ calcd for C32H57N2O5Se, 629.3433; found 629.3431.
1721 (2R)-Boc-amino-N-(4′-hydroxy-3′-methoxybenzyl)-3-(octa-
1722 dec-(9″Z)-en-1-ylseleno)propanamide (59). General procedure
1723 III was applied to compound 27 (200 mg, 0.25 mmol), NaBH4 (24
1724 mg, 0.62 mmol) and compound 30b (212 mg, 0.56 mmol) dissolved
1725 in EtOH (2 mL). Compound 59 was aﬀorded after silica gel column
1726 chromatography (petroleum ether/EtOAc 6:4) as a yellow oil (287
1727 mg, 88%). Rf = 0.66 (petroleum ether/EtOAc 7:3). [α]D
20 −4.90 (c
1728 1.4, DCM). IR (ATR) ν = 3444, 3337, 2919, 2850, 1676, 1511 cm−1.
1729
1H NMR (400 MHz, CDCl3) δ = 0.88 (t, 3H, J = 6.9 Hz, CH3),
17301.16−1.39 (m, 22H, CH2), 1.42 (s, 9H, C(CH3)3), 1.57−1.68 (m,
17312H, SeCH2CH2), 2.01 (q, 4H, J = 6.4 Hz, CH2CH, CHCH2), 2.44−
17322.70 (m, 2H, SeCH2CH2), 2.83 (dd, 1H, J = 12.8, 6.9 Hz,
1733CHCH2Se), 3.05 (dd, 1H, J = 12.8, 5.2 Hz, CHCH2Se), 3.88 (s,
17343H, CH3O), 4.26−4.35 (m, CHCH2Se), 4.37 (d, 2H, J = 5.7 Hz,
1735CH2NH), 5.23−5.43 (m, 3H, CHCH, CH2NH), 5.60 (s, 1H, OH),
17366.56 (t, 1H, J = 5.5 Hz, NHBoc), 6.79 (ddd, 3H, J = 12.5, 9.9, 5.0 Hz,
1737HAr).
13C NMR (101 MHz, CDCl3) δ = 14.10 (CH3), 22.66 (CH2),
173825.36 (SeCH2CH2), 25.90 (CHCH2Se), 27.18 (CH2CH), 27.20
1739(CHCH2), 28.24 (C(CH3)3), 29.11 (CH2), 29.23 (CH2), 29.30 (2 ×
1740CH2), 29.41 (CH2), 29.50 (CH2), 29.72 (CH2), 29.75 (CH2), 29.80
1741(CH2), 30.50 (CH2), 31.88 (CH2), 43.55 (CH2NH), 54.42
1742(CHCH2Se), 55.95 (CH3O), 80.57 (C(CH3)3), 110.48 (CAr),
1743114.31 (CAr), 120.66 (CAr), 129.68 (CAr), 129.76 (CHCH),
1744129.95 (CHCH), 145.10 (CAr), 146.65 (CAr), 155.54 (NHCO2),
1745170.43 (NHCO). HR-MS (ESI+), m/z: [M + H]+ calcd for
1746 gC34H59N2O5Se, 655.3589; found 655.3583.
17472-(Hexadecylseleno)-1-[N-(4′-hydroxy-3′-methoxybenzyl)-
1748carbamoyl]-(1R)-ethylammonium Triﬂuoroacetate (60). Gen-
1749eral procedure IX was applied to compound 58 (200 mg, 0.32 mmol),
1750TFA (240 μL, 3.2 mmol) in DCM (1 mL). Compound 60 was
1751aﬀorded after ﬂushing nitrogen and drying in vacuo as a yellow oil
1752(201 mg, quantitative). [α]D
20 0.65 (c 1.4, MeOH). IR (ATR) ν =
17533425, 3316, 2916, 2849, 1658, 1187 cm−1. 1H NMR (400 MHz,
1754CDCl3) δ = 0.88 (t, 3H, J = 6.9 Hz, CH3), 1.20−1.34 (m, 26H, CH2),
17551.53−1.61 (m, 2H, SeCH2CH2), 2.55 (t, 2H, J = 6.9 Hz, SeCH2CH2),
17562.85−3.01 (m, 2H, CHCH2Se), 3.82 (s, 3H, CH3O), 4.21−4.37 (m,
17573H, CHCH2Se, CH2NH), 6.73 (ddd, 3H, J = 12.5, 9.9, 5.0 Hz, HAr),
17587.53 (t, 1H, J = 5.0 Hz, CH2NH), 7.98 (br s, 1H, OH), 9.42 (br s, 2H,
1759NH2).
13C NMR (101 MHz, CDCl3) δ = 14.25 (CH3), 22.84 (CH2),
176023.51 (CHCH2Se), 25.89 (CH2), 27.72 (CH2), 29.22 (CH2), 29.51
1761(CH2), 29.64 (CH2), 29.73 (CH2), 29.80 (CH2), 29.81 (CH2), 29.83
1762(CH2), 29.85 (3 × CH2), 30.19 (CH2), 32.08 (CH2), 44.50
1763(CH2NH), 53.54 (CHCH2Se), 55.94 (CH3O), 110.72 (CAr),
1764114.77 (CAr), 116.78 (CF3COOH), 120.96 (CAr), 128.09 (CAr),
1765145.43 (CAr), 146.96 (CAr), 160.81−162.0 (CF3COOH), 167.72
1766(NHCO). HR-MS (ESI+), m/z: [M + H]+ calcd for C27H49N2O3Se,
1767 g529.2903; found 529.2905.
17681-[N-(4′-Hydroxy-3′-methoxybenzyl)carbamoyl]-2-(octa-
1769dec-(9″Z)-en-1-ylseleno)-(1R)-ethylammonium Triﬂuoroace-
1770tate (61). General procedure IX was applied to compound 59 (200
1771mg, 0.30 mmol), TFA (230 μL, 3 mmol) in DCM (1 mL).
1772Compound 61 was aﬀorded after ﬂushing nitrogen and drying in
1773vacuo as a yellow oil (199 mg, quantitative). [α]D
20 −2.58 (c 0.3,
1774DCM). IR (ATR) ν = 2922, 2853, 1666, 1199 cm−1. 1H NMR (400
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1775 MHz, CDCl3) δ = 0.87 (t, 3H, J = 6.9 Hz, CH3), 1.22−1.34 (m, 22H,
1776 CH2), 1.51−1.61 (m, 2H, SeCH2CH2), 2.00 (q, 4H, J = 6.4 Hz,,
1777 CH2CH, CHCH2), 2.54 (t, 2H, J = 6.9 Hz, SeCH2CH2), 2.93 (d, 2H,
1778 J = 6.4 Hz, CHCH2Se), 3.81 (s, 3H, CH3O), 4.17−4.34 (m, 3H,
1779 CHCH2Se, CH2NH), 5.28−5.42 (m, 2H, CHCH), 6.72 (ddd, 3H,
1780 J = 12.5, 9.9, 5.0 Hz, HAr), 7.64 (t, 1H, J = 5.5 Hz, CH2NH).
13C
1781 NMR (101 MHz, CDCl3) δ = 14.26 (CH3), 22.83 (CH2), 23.56
1782 (CHCH2Se), 25.89 (SeCH2CH2), 27.37 (CH2CH, CHCH2), 29.24
1783 (CH2), 29.42 (CH2), 29.47 (CH2), 29.47 (CH2), 29.59 (CH2), 29.68
1784 (CH2), 29.87 (CH2), 29.91 (CH2), 29.92 (CH2), 30.26 (CH2), 32.06
1785 (CH2), 44.17 (CH2NH), 53.40 (CHCH2Se), 56.00 (CH3O), 110.73
1786 (CAr), 114.68 (CAr), 120.87 (CAr), 128.61 (CAr), 129.90 (CHCH),
1787 130.12 (CHCH), 145.38 (CAr), 146.93 (CAr), 167.76 (NHCO).
1788 HR-MS (ESI+), m/z: [M + H]+ calcd for C29H51N2O3Se, 555.3059;
g 1789 found 555.3067.
1790 (13Z)-Docosenoic Acid (63a). General procedure II was applied
1791 to a solution of methyl (13Z)-docosenoate 62a (500 μL, 1.23 mmol)
1792 dissolved in THF/H2O (6 mL, 1:1) and LiOH·H2O (155 mg, 3.70
1793 mmol) to yield compound 63a as a white solid (360 mg, 86%). Mp:
1794 30−32 °C. IR (ATR) ν = 2916, 2849, 1691, 1471 cm−1. 1H NMR
1795 (400 MHz, CDCl3) δ = 0.88 (t, 3H, J = 6.9 Hz, CH3), 1.17−1.39 (m,
1796 28H, CH2), 1.58−1.70 (m, 2H, OHCOCH2CH2), 2.02 (q, 4H, J =
1797 6.4 Hz, CH2CH, CHCH2), 2.34 (t, 2H, J = 6.9 Hz, OHCOCH2CH2),
1798 5.24−5.42 (m, 2H, CHCH). 13C NMR (101 MHz, CDCl3) δ =
1799 14.09 (CH3), 22.67 (CH2), 24.67 (OHCOCH2CH2), 27.20 (CH2CH,
1800 CHCH2), 29.05 (CH2), 29.23 (CH2), 29.30 (CH2), 29.31 (2 × CH2),
1801 29.42 (CH2), 29.51 (CH2), 29.53 (CH2), 29.57 (CH2), 29.59 (CH2),
1802 29.76 (2 × CH2), 31.90 (CH2), 34.01 (OHCOCH2CH2), 129.86
1803 (CHCH), 129.89 (CHCH), 179.89 (OHCOCH2CH2).
1804 (13Z,16Z)-Docosadienoic Acid (63b). General procedure II was
1805 applied to a solution of methyl (13Z,16Z)-docosadienoate 62b (25
1806 μL, 0.07 mmol) in THF/H2O (1 mL, 1:1) and LiOH·H2O (9 mg,
1807 0.21 mmol) to yield compound 63b20 as a sticky solid (23 mg,
1808 quantitative). IR (ATR) ν = 2922, 2853, 1708, 1458 cm−1. 1H NMR
1809 (400 MHz, CDCl3) δ = 0.89 (t, 3H, J = 6.9 Hz, CH3), 1.17−1.45 (m,
1810 22H, CH2), 1.53−1.72 (m, 2H, COCH2CH2), 2.05 (q, 4H, J = 6.4
1811 Hz, CH2CH, CHCH2), 2.34 (t, 2H, J = 6.9 Hz, COCH2CH2), 2.77 (t,
1812 2H, J = 6.9 Hz, CHCH2CH), 5.24−5.44 (m, 4H, 2 × CHCH). 13C
1813 NMR (101 MHz, CDCl3) δ = 14.07 (CH3), 22.58 (CH2), 24.68
1814 (OHCOCH2CH2), 25.63 (CHCH2CH), 27.20 (CH2CH), 27.24
1815 (CHCH2), 29.07 (CH2), 29.24 (CH2), 29.32 (CH2), 29.36 (CH2),
1816 29.43 (CH2), 29.54 (CH2), 29.58 (CH2), 29.60 (CH2), 29.68 (CH2),
1817 31.53 (CH2), 34.05 (OHCOCH2CH2), 127.94 (2 × CHCH),
g 1818 130.17 (2 × CHCH), 179.96 (OHCOCH2CH2).
1819 N-(4′-Hydroxy-3′-methoxybenzyl)docosa-(13Z)-enamide
1820 (64). General procedure I was applied to a solution of compound 63a
1821 (200 mg, 0.59 mmol) in anhydrous DMF (5 mL), amine
1822 hydrochloride salt 3 (123 mg, 0.65 mmol), DIPEA (309 μL, 1.77
1823 mmol), and HATU (337 mg, 0.88 mmol). Compound 64 was
1824 aﬀorded after silica gel column chromatography (petroleum ether/
1825 EtOAc 6:4) as a sticky solid (179 mg, 64%). Rf = 0.42 (petroleum
1826 ether/EtOAc 5:5). IR (ATR) ν = 3489, 3315, 3304, 2918, 2849,
1827 1648, 1465 cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.88 (t, 3H, J =
1828 6.9 Hz, CH3), 1.23−1.36 (m, 28H, CH2), 1.59−1.69 (m, 2H,
1829 COCH2CH2), 2.01 (q, 4H, J = 6.4 Hz, CH2CH, CHCH2), 2.19 (t,
1830 2H, J = 6.9 Hz, COCH2CH2), 3.87 (s, 3H, CH3O), 4.34 (d, 2H, J =
1831 5.7 Hz, CH2NH), 5.29−5.39 (m, 2H, CHCH), 5.69 (s, 2H, OH,
1832 CH2NH), 6.79 (ddd, 3H, J = 12.5, 9.9, 5.0 Hz, HAr).
13C NMR (101
1833MHz, CDCl3) δ = 14.25 (CH3), 22.82 (CH2), 25.94 (COCH2CH2),
183427.35 (CH2CH, CHCH2), 29.46 (3 × CH2), 29.50 (CH2), 29.66 (2 ×
1835CH2), 29.69 (CH2), 29.75 (2 × CH2), 29.83 (CH2), 29.91 (CH2),
183629.92 (CH2), 32.04 (CH2), 37.00 (COCH2CH2), 43.66 (CH2NH),
183756.05 (CH3O), 110.82 (CAr), 114.50 (CAr), 120.92 (CAr), 130.00
1838(CHCH), 130.04 (CHCH), 130.51 (CAr), 145.26 (CAr), 146.83
1839(CAr), 173.04 (COCH2CH2). HR-MS (ESI
+), m/z: [M + Na]+ calcd
1840 gfor C30H51NO3Na, 496.3767; found 496.3756.
1841N-(4′-Hydroxy-3′-methoxybenzyl)docosa-(13Z,16Z)-diena-
1842mide (65). General procedure I was applied to a solution of
1843compound 63b (23 mg, 0.07 mmol) dissolved in DMF (1 mL), amine
1844hydrochloride salt 3 (15 mg, 0.08 mmol), DIPEA (38 μL, 0.21
1845mmol), and HATU (39 mg, 0.10 mmol). Compound 65 was aﬀorded
1846after silica gel column chromatography (petroleum ether/EtOAc 6:4)
1847as a sticky oil (21 mg, 63%). Rf = 0.40 (petroleum ether/EtOAc 5:5).
1848IR (ATR) ν = 3489, 3316, 3302, 2919, 2849, 1639, 1518 cm−1. 1H
1849NMR (400 MHz, CDCl3) δ = 0.89 (t, 3H, J = 6.9 Hz, CH3), 1.24−
18501.38 (m, 22H, CH2), 1.59−1.70 (m, 2H, COCH2CH2), 2.05 (q, 4H, J
1851= 6.4 Hz, CH2CH, CHCH2), 2.19 (t, 2H, J = 6.9 Hz, COCH2CH2),
18522.77 (t, 2H, J = 6.9 Hz, CHCH2CH), 3.87 (s, 3H, CH3O), 4.35 (d,
18532H, J = 5.7 Hz, CH2NH), 5.28−5.43 (m, 4H, 2 × CHCH), 5.59−
18545.72 (m, 2H, OH, CH2NH), 6.79 (ddd, 3H, J = 12.5, 9.9, 5.0 Hz,
1855HAr).
13C NMR (101 MHz, CDCl3) δ = 14.22 (CH3), 22.72 (CH2),
185625.78 (CHCH2CH), 25.94 (COCH2CH2), 27.35 (CH2CH), 27.39
1857(CHCH2), 29.48 (2 × CH2), 29.50 (2 × CH2), 29.65 (CH2), 29.70
1858(CH2), 29.75 (2 × CH2), 29.83 (CH2), 31.68 (CH2), 37.03
1859(COCH2CH2), 43.68 (CH2NH), 56.08 (CH3O), 110.82 (CAr),
1860114.49 (CAr), 120.95 (CAr), 128.09 (2 × CHCH), 130.31
1861(CHCH), 130.34 (CHCH), 130.53 (CAr), 145.26 (CAr),
1862146.82 (CAr), 173.05 (COCH2CH2). HR-MS (ESI
+), m/z: [M +
1863 gNa]+ calcd for C30H49NO3Na, 494.3610; found 494.3606.
1864Hexadecanohydrazide (66). To a suspension of methyl
1865palmitate 28a (1 g, 3.69 mmol) in ethanol (20 mL), hydrazyne
1866hydrate (64%, 370 μL, 7.38 mmol, 2 equiv) was added. Then, the
1867mixture was heated at 150 °C for 3 h. The mixture was cooled, and
1868the solid precipitated was recovered by ﬁltration to yield compound
18696621 as a white solid (800 mg, 80%). Mp: 110−111 °C. IR (ATR) ν =
18703315, 3288, 3199, 2956, 2917, 2848, 1627, 1535 cm−1. 1H NMR (400
1871MHz, CDCl3) δ = 0.88 (t, 3H, J = 6.9 Hz, CH3), 1.06−1.42 (m, 24H,
1872CH2), 1.55−1.74 (m 2H, NHCOCH2CH2), 2.08−2.23 (m, 2H,
1873NHCOCH2CH2), 3.89 (br s, 2H, NH2NH), 6.66 (s, 1H, NH2NH).
1874
13C NMR (101 MHz, CDCl3) δ = 14.10 (CH3), 22.67 (CH2), 25.48
1875(NHCOCH2CH2), 29.25 (CH2), 29.27 (CH2), 29.34 (CH2), 29.44
1876(CH2), 29.57 (CH2), 29.62 (CH2), 29.63 (CH2), 29.64 (CH2), 29.66
1877(CH2), 29.67 (CH2), 31.90 (CH2), 34.59 (NHCOCH2CH2), 173.97
1878 g(NHCOCH2).
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1879 N′-(4′-Hydroxy-3′-methoxybenzylidene)hexadecano-
1880 hydrazide (67). General procedure X was applied to compound 66
1881 (280 mg, 1.03 mmol), vanillin 1 (157 mg, 1.03 mmol), AcOH (60 μL,
1882 1.03 mmol) in MeOH (30 mL). Compound 67 was aﬀorded as a
1883 white solid (242 mg, 58%) after recrystallization from hot MeOH.
1884 The 1H NMR analysis conﬁrmed the presence of the cis isomer of the
1885 imine as the minor product. Mp: 109−110 °C. IR (ATR) ν = 3202,
1886 3054, 2917, 2849, 1659, 1510 cm−1. Trans isomer: 1H NMR (400
1887 MHz, CDCl3) δ = 0.88 (t, 3H, J = 6.9 Hz, CH3), 1.23−1.42 (m, 24H,
1888 CH2), 1.69−1.78 (m, 2H, NHCOCH2CH2), 2.74 (t, 2H, J = 6.9 Hz,
1889 NHCOCH2CH2), 3.95 (s, 3H, CH3O), 5.86 (s, 1H, OH), 6.93 (d,
1890 1H, J = 8.2 Hz, HAr), 7.09 (dd, 1H, J = 8.2, 1.8 Hz, HAr), 7.25 (d, 1H,
1891 J = 1.8 Hz, HAr), 7.65 (s, 1H, HCNNH), 9.02 (s, 1H, NHCO). Cis
1892 isomer: 1H NMR (400 MHz, CDCl3) δ = 2.28 (t, 2H, J = 6.9 Hz,
1893 NHCOCH2CH2), 3.94 (s, 1H, CH3OH), 5.91 (br s, 1H, OH), 6.89
1894 (d, 1H, J = 8.2 Hz, HAr), 6.98 (dd, 1H, J = 8.2, 1.8 Hz, HAr), 7.49 (br
1895 s, 1H, HAr), 8.00 (s, 1H, HCNNH), 8.46 (s, 1H, NHCO). The rest
1896 of signals are common to trans isomer. Trans isomer: 13C NMR (101
1897 MHz, CDCl3) δ = 14.27 (CH3), 22.85 (NHCOCH2CH2), 24.97
1898 (CH2), 29.51 (CH2), 29.59 (CH2), 29.64 (CH2), 29.72 (CH2), 29.81
1899 (2 × CH2), 29.85 (4 × CH2), 32.08 (CH2), 32.96 (NHCOCH2CH2),
1900 56.09 (CH3O), 107.97 (CAr), 114.61 (CAr), 122.37 (CAr), 126.49
1901 (CAr), 143.20 (HCNNH), 147.07 (CAr), 147.90 (CAr), 176.00
1902 (NHCO). Cis isomer: 13C NMR (101 MHz, CDCl3) δ = 56.38
1903 (CH3O), 107.86 (CAr), 114.13 (CAr), 123.80 (CAr), 126.20 (CAr).
1904 The rest of signals are common to trans isomer. HR-MS (ESI+), m/z:
g 1905 [M + Na]+ calcd for C48H80N4O6Na, 831.5976; found 831.5968.
1906 tert-Butyl Hydrazinecarboxylate (69). Hydrazyne hydrate 68
1907 (64%, 1.52 mL, 31.2 mmol) was mixed with isopropanol (3 mL) at 0
1908 °C. Then, a solution of Boc2O (6.8 g, 31.2 mmol, 1 equiv) in
1909 isopropanol (6 mL) was added dropwise. The reaction mixture turned
1910 cloudy upon addition and was stirred at room temperature for 2 h.
1911 The solvent was removed under reduced pressure and the residue was
1912 dissolved in DCM, washed with 1 M HCl and brine. The organic
1913 phase was dried over Na2SO4, and the solvent was removed under
1914 reduced pressure. The residue was recrystallized from hexane to yield
1915 compound 6922 as a white solid (1.94 g, 47%). Mp: 38−40 °C. IR
1916 (ATR) ν = 3374, 3324, 2981, 1692, 1627, 1502 cm−1. 1H NMR (400
1917 MHz, CDCl3) δ = 1.44 (s, 9H, C(CH3)3), 3.57 (s, 2H, NH2) 6.00 (s,
1918 1H, NHCO). 13C NMR (101 MHz, CDCl3) δ = 28.28 (C(CH3)3),
g 1919 80.42 (C(CH3)3), 158.22 (COO).
1920 N′-(tert-Butyloxycarbonyl)octadec-(9Z)-enohydrazide (70).
1921 General procedure I was applied to a solution of oleic acid 70 (1 g,
1922 3.54 mmol) dissolved in DMF (30 mL), compound 69 (524 mg, 3.96
1923 mmol), DIPEA (1.85 mL, 10.62 mmol), and HATU (2.02 g, 5.31
1924 mmol). Compound 7123 was aﬀorded after silica gel column
1925 chromatography (petroleum ether/EtOAc 7:3) as a yellow oil (1.32
1926 g, 94%). Rf = 0.47 (petroleum ether/EtOAc 6:4). IR (ATR) ν = 3280,
1927 2924, 2854, 1729, 1673, 1242 cm−1. 1H NMR (400 MHz, CDCl3) δ =
1928 0.86 (t, 3H, J = 6.9 Hz, CH3), 1.16−1.40 (m, 20H, CH2) 1.44 (s, 9H,
1929 C(CH3)3), 1.57−1.74 (m, 2H, NHCOCH2CH2), 1.90−2.07 (m, 4H,
1930 CH2CH, CHCH2), 2.11−2.28 (m, 2H, NHCOCH2CH2), 5.22−5.43
1931 (m, 2H, CHCH), 6.85 (s, 1H, NHNH), 8.06 (s, 1H, NHNH). 13C
1932 NMR (101 MHz, CDCl3) δ = 14.07 (CH3), 22.64 (CH2), 25.25
1933 (NHCOCH2CH2), 27.14 (CH2CH), 27.18 (CHCH2), 28.11 (C-
1934 (CH3)3), 29.08 (CH2), 29.17 (CH2), 29.19 (CH2), 29.27 (CH2),
1935 29.29 (CH2), 29.48 (CH2), 29.67 (CH2), 29.72 (CH2), 31.86 (CH2),
1936 33.97 (NHCOCH2CH2), 81.66 (C(CH3)3), 129.68 (CHCH),
g 1937 129.93 (CHCH), 155.85 (COC(CH3)3), 172.80 (NHCOCH2).
1938Oleylhydrazine (72). To a solution of compound 71 (1 g, 2.52
1939mmol) in DCM (3 mL), TFA (1.93 mL, 25.2 mmol, 10 equiv) was
1940added. The mixture was stirred for 2 h at room temperature. Then,
1941the solvent was partially evaporated. Water was added, and the pH
1942was adjusted to 7 with saturated solution of NaHCO3. The aqueous
1943phase was extracted with DCM, and the organic solution was dried
1944over Na2SO4 and ﬁltered. The solvent was removed under reduced
1945pressure to yield the compound 72 as a yellow solid (687 mg, 92%).
1946Mp: 109−110 °C. IR (ATR) ν = 3316, 3214, 2919, 2849, 1628, 1596
1947cm−1. 1H NMR (400 MHz, CDCl3) δ = 0.87 (t, 3H, J = 6.9 Hz, CH3),
19481.12−1.42 (m, 20H, CH2) 1.53−1.74 (m, 2H, NHCOCH2CH2),
19491.88−2.05 (m, 4H, CH2CH, CHCH2), 2.08−2.24 (m, 2H,
1950NHCOCH2CH2), 3.97 (s, 2H, H2N), 5.20−5.43 (m, 2H, CH
1951CH), 6.84 (s, 1H, NH). 13C NMR (101 MHz, CDCl3) δ = 14.08
1952(CH3), 22.65 (CH2), 25.46 (NHCOCH2CH2), 27.13 (CH2CH),
195327.19 (CHCH2), 29.07 (CH2), 29.18 (CH2), 29.22 (CH2), 29.29 (2 ×
1954CH2), 29.49 (CH2), 29.66 (CH2), 29.73 (CH2), 31.87 (CH2), 34.55
1955(NHCOCH2CH2), 129.67 (CHCH), 129.99 (CHCH), 173.98
1956 g(NHCOCH2).
1957N′-(4′-Hydroxy-3′-methoxybenzylidene)octadec-(9Z)-eno-
1958hydrazide (73). General procedure X was applied to compound 72
1959(300 mg, 1.01 mmol), vanillin 1 (153 mg, 1.01 mmol), AcOH (60 μL,
19601.01 mmol) in MeOH (30 mL). Compound 73 was aﬀorded after
1961silica gel column chromatography (petroleum ether/EtOAc 6:4) as a
1962colorless oil (1.32 g, 94%). The 1H NMR analysis conﬁrmed the
1963presence of the cis isomer of the imine as a minor product. IR (ATR)
1964ν = 3452, 3194, 2921, 2852, 1650, 1211 cm−1. Trans isomer: 1H
1965NMR (400 MHz, CDCl3) δ = 0.87 (t, 3H, J = 6.9 Hz, CH3), 1.22−
19661.43 (m, 20H, CH2), 1.69−1.78 (m, 2H, NHCOCH2CH2), 1.94−
19672.07 (m, 4H, CH2CH, CHCH2), 2.74 (t, 2H, J = 6.9 Hz,
1968NHCOCH2CH2), 3.95 (s, 3H, CH3O), 5.31−5.36 (m, 2H, CH
1969CH), 5.93 (br s, 1H, OH), 6.93 (d, 1H, J = 8.2 Hz, HAr), 7.10 (dd,
19701H, J = 8.2, 1.8 Hz, HAr), 7.25 (d, 1H, J = 1.8 Hz, HAr), 7.69 (s, 1H,
1971HCNNH), 9.43 (s, 1H, NHCO). Cis isomer: 1H NMR (400 MHz,
1972CDCl3) δ = 2.28 (t, 2H, J = 6.9 Hz, NHCOCH2CH2), 3.93 (s, 1H,
1973CH3OH), 5.36−5.39 (m, 2H, CHCH), 5.97 (br s, 1H, OH), 6.89
1974(d, 1H, J = 8.2 Hz, HAr), 6.97 (dd, 1H, J = 8.2, 1.8 Hz, HAr), 7.49 (d,
19751H, J = 1.8 Hz, HAr), 8.00 (s, 1H, HCNNH), 8.62 (s, 1H, NHCO).
1976The rest of signals are common to trans isomer. Trans isomer: 13C
1977NMR (101 MHz, CDCl3) δ = 14.26 (CH3), 22.82 (NHCOCH2CH2),
197825.00 (CH2), 27.34 (CH2CH), 27.36 (CHCH2), 29.35 (CH2), 29.46
1979(CH2), 29.46 (CH2), 29.49 (CH2), 29.61 (CH2), 29.66 (CH2), 29.84
1980(CH2), 29.91 (CH2), 32.04 (CH2), 32.94 (NHCOCH2CH2), 56.08
1981(CH3O), 108.06 (CAr), 114.63 (CAr), 122.32 (CAr), 126.54 (CAr),
1982129.88 (CHCH), 130.13 (CHCH), 143.54 (HCNNH),
1983147.06 (CAr), 147.89 (CAr), 176.30 (NHCO). Cis isomer:
13C NMR
1984(101 MHz, CDCl3) δ = 56.35 (CH3O), 107.87 (CAr), 114.11 (CAr),
1985123.79 (CAr), 126.16 (CAr), 147.24 (CAr), 147.73 (CAr). The rest of
1986signals are common to trans isomer. HR-MS (ESI+), m/z: [M + Na]+
1987calcd for C52H84N4O6Na, 883.6289; found 883.6286.
19885.3. TRP Channels Assays. Assays of TRP-mediated elevation of
1989[Ca2+]i were performed as previously described.
60 HEK-293 (human
1990embryonic kidney) cells wild-type or stably overexpressing recombi-
1991nant human TRPV1 or rat TRPV2 were grown on 100 mm diameter
Journal of Medicinal Chemistry Article
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1992 Petri dishes as monolayers in Eagle’s minimum essential medium
1993 (EMEM) supplemented with 1% nonessential amino acids, 10% fetal
1994 bovine serum (FBS), 50 U/mL penicillin plus 50 μg/mL
1995 streptomycin, and 2 mM glutamine, maintained under 5% CO2 at
1996 37 °C and only for the overexpressing cells selected by G-418
1997 (Geneticin, 600 mg mL−1; Thermo-Fisher Scientiﬁc). On the day of
1998 the experiment, the cells were loaded for 1 h at 25 °C with the Ca2+
1999 indicator Fluo-4-AM (Thermo-Fisher Scientiﬁc) 4 μM in DMSO
2000 containing 0.02% Pluronic F-127 (Thermo-Fisher Scientiﬁc) in
2001 EMEM without FBS. After loading, cells were washed twice in
2002 Tyrode’s buﬀer (145 mM NaCl, 2.5 mM KCl, 1.5 mM CaCl2, 1.2 mM
2003 MgCl2, 10 mM D-glucose, and 10 mM HEPES, pH 7.4), resuspended
2004 in the same buﬀer, and transferred, about 100 000 cells for each
2005 determination, to the quartz cuvette of the spectroﬂuorimeter (λex =
2006 488 nm; λem = 516 nm) PerkinElmer LS50B equipped with PTP-1
2007 ﬂuorescence Peltier system (PerkinElmer Life and Analytical Sciences,
2008 Waltham, MA, USA) under continuous stirring at 25 °C. Experiments
2009 were carried by measuring cell ﬂuorescence before and after the
2010 addition of test compounds at various concentrations. The values of
2011 the eﬀect on [Ca2+]i in wild-type (i.e., not transfected with any TRP
2012 construct) HEK-293 cells were taken as baselines. Potency (EC50
2013 values) was determined as the concentration of test compounds
2014 exerting a half-maximal agonist eﬀect (i.e., half-maximal increases in
2015 [Ca2+]i). The eﬃcacy of the agonists was determined by comparing
2016 their eﬀect to the maximal eﬀect on [Ca2+]i observed with 4 μM
2017 ionomycin. Antagonist/desensitizing behavior was evaluated against
2018 the agonist capsaicin 0.1 μM (Sigma-Aldrich) for TRPV1 and the
2019 agonists lysophosphatidylcholine (LPC) (Sigma-Aldrich) 3 μM and
2020 cannabidiol (CBD) 2 μM (a kind gift by GW Pharmaceuticals) for
2021 TRPV2 by adding the test compounds in the quartz cuvette 5 min
2022 before stimulation of cells with the agonist. The eﬀect on [Ca2+]i
2023 exerted by agonist alone was taken as 100%. Data are expressed as the
2024 concentration exerting a half-maximal inhibition of agonist-induced
2025 [Ca2+]i elevation (IC50). Concentration−response curves were ﬁtted
2026 by a sigmoidal regression with variable slope. Curve ﬁtting and
2027 parameter estimation were performed with GraphPad Prism (Graph-
2028 Pad Software Inc., San Diego, CA). Determinations were performed
2029 at least in triplicate. Statistical analysis of the data was performed by
2030 analysis of variance at each point using ANOVA followed by
2031 Bonferroni’s test.
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